

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

Jens Wrarmert,^{1,2} Dimitrios Koutsouanos,² Gui-Mei Li,^{1,2} Srilatha Edupuganti,^{4,5} Jianhua Sui,⁶ Michael Morrissey,⁸ Megan McCausland,^{1,2} Ioanna Skountzou,² Mady Hornig,⁹ W. Ian Lipkin,⁹ Aneesh Mehta,³ Behzad Razavi,⁵ Carlos Del Rio,^{3,4,10} Nai-Ying Zheng,⁸ Jane-Hwei Lee,⁸ Min Huang,⁸ Zahida Ali,⁸ Kaval Kaur,⁸ Sarah Andrews,⁸ Rama Rao Amara,^{1,2} Youliang Wang,¹ Suman Ranjan Das,¹¹ Christopher David O'Donnell,¹² Jon W. Yewdell,¹¹ Kanta Subbarao,¹² Wayne A. Marasco,⁶ Mark J. Mulligan,⁴ Richard Compans,¹ Rafi Ahmed,^{1,2} and Patrick C. Wilson⁸

¹Emory Vaccine Center, ²Department of Microbiology and Immunology, ³Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30322

⁴Hope Clinic of the Emory Vaccine Center, School of Medicine, Division of Infectious Disease, Decatur, Georgia, 30030

⁵Department of Internal Medicine, Emory University, Atlanta, GA 30322

⁶Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute

⁷Department of Medicine, Harvard Medical School, Boston, MA 02115

⁸Department of Medicine, Section of Rheumatology, The Committee on Immunology, The Knapp Center for Lupus and Immunology Research, The University of Chicago, Chicago, IL 60637

⁹Center for Infection and Immunity, Columbia University Mailman School of Public Health, New York, NY 10032

¹⁰Hubert Department of Global Health, Rollins School of Public Health and Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322

¹¹Laboratory of Viral Diseases, ¹²Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892

The 2009 pandemic H1N1 influenza pandemic demonstrated the global health threat of reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and monoclonal antibody responses induced by pandemic H1N1 infection in humans. Unlike antibodies elicited by annual influenza vaccinations, most neutralizing antibodies induced by pandemic H1N1 infection were broadly cross-reactive against epitopes in the hemagglutinin (HA) stalk and head domain of multiple influenza strains. The antibodies were from cells that had undergone extensive affinity maturation. Based on these observations, we postulate that the plasmablasts producing these broadly neutralizing antibodies were predominantly derived from activated memory B cells specific for epitopes conserved in several influenza strains. Consequently, most neutralizing antibodies were broadly reactive against divergent H1N1 and H5N1 influenza strains. This suggests that a pan-influenza vaccine may be possible, given the right immunogen. Antibodies generated potentially protected and rescued mice from lethal challenge with pandemic H1N1 or antigenically distinct influenza strains, making them excellent therapeutic candidates.

CORRESPONDENCE

Rafi Ahmed:

rahmed@emory.edu

OR

Patrick C. Wilson:

wilsonp@uchicago.edu

Abbreviations used: GC, germinal center; HA, hemagglutinin; HAI, hemagglutinin inhibition; MN, microneutralization; TCID₅₀, 50% tissue culture infectious dose.

Influenza is the seventh leading cause of death in the United States (Beigel, 2008), with the elderly, the very young, pregnant women, and otherwise immune-compromised populations accounting for >90% of influenza-related deaths. The pandemic H1N1 influenza virus strain is immunologically distinct from other influenza

viruses, leaving large population groups susceptible to infection (Brockwell-Staats et al., 2009; Dawood et al., 2009; Garten et al., 2009;

© 2011 Wrarmert et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).

Hancock et al., 2009). The Centers for Disease Control reports that there were an estimated 60 million cases of the 2009 H1N1 pandemic strain, which caused ~256,000 hospitalizations. An unusually high frequency of severe disease occurred in younger and otherwise healthy patients (Hancock et al., 2009). In addition, rare infections with avian H5N1 influenza strains in humans had close to a 50% mortality rate (Subbarao and Joseph, 2007). Emergence of a zoonotic or antigenically distinct strain that combined even a fraction of the morbidity and mortality of the pandemic H1N1 and H5N1 viruses would have dire consequences. Antibodies play a key role in protection against influenza infection in vivo (Puck et al., 1980; Gerhard et al., 1997; Luke et al., 2006; Simmons et al., 2007). The fact that there were little or no preexisting antibody titers present before the emergence of this pandemic virus, and that the virus atypically caused such severe disease in young adult, illustrates the importance of comprehensively understanding the B cell responses and antibody specificities induced by infection with this influenza virus.

Here, we have analyzed the plasmablast responses induced by pandemic H1N1 infection and generated a panel of monoclonal antibodies (mAbs) from these cells to analyze their characteristics in detail. In contrast to seasonal vaccination, we show that a majority of the neutralizing antibodies induced by infection were broadly cross-reactive with all recent annual H1N1 strains, as well as the highly pathogenic 1918 H1N1 and avian H5N1 strains. These neutralizing antibodies bound predominantly to conserved epitopes in the hemagglutinin (HA) stalk region (Ekiert et al., 2009; Sui et al., 2009), with some binding to novel epitopes in the HA globular head. The high frequency of these HA-stalk binding antibodies is of particular interest, as this epitope is a promising target for a broadly protective influenza vaccine (Steel et al., 2010). Furthermore, the cross-reactive antibodies carried highly mutated immunoglobulin genes, indicative of extensive affinity maturation. Together, these findings support a model in which infection predominantly activated broadly cross-reactive memory B cells that then underwent further affinity maturation. We propose that the expansion of these rare types of memory B cells may explain why most people did not become severely ill, even in the absence of preexisting protective antibody titers. Recent studies in mice strongly support the idea that consecutive immunizations with antigens from divergent influenza strains can indeed hone the antibody response to preferentially target broadly protective conserved epitopes (Wang et al., 2010; Wei et al., 2010). Our findings demonstrate that cross-reactive antibodies can be preferentially induced in humans given the right immunogen, providing further support for the feasibility of generating a pan-influenza vaccine. Finally, in vivo challenge experiments showed that the neutralizing antibodies isolated protected mice challenged with a lethal dose of pandemic H1N1 influenza virus, even when administered therapeutically 72 h after infection, and also provided protection against antigenically distinct H1N1 influenza strains. These antibodies are thus promising as therapeutics against pandemic H1N1, as well as

most other H1N1 and H5N1 influenza strains, especially in high-risk populations such as immunosuppressed patients and the elderly.

RESULTS

Influenza-specific plasmablasts are persistently induced throughout infection, providing a rich source of antiviral mAbs

B cell responses were examined in nine patients infected with the pandemic 2009 H1N1 influenza virus. These patients had varying courses and severity of disease. The cases ranged from mild disease with rapid viral clearance within a few days after onset of symptoms to severe cases that shed virus for several weeks and required hospitalization with ventilator support. A majority of the patients were treated with antiviral drugs. The diagnoses were confirmed by pandemic H1N1-specific RT-PCR and serology. All patients had neutralizing titers of serum antibodies at the time of blood collection. A summary of the clinical patient data are shown in Table I. The majority of samples were obtained around 10 d after the onset of symptoms, with the exception of a particularly severe case where sampling was done 31 d after symptom onset.

Antigen-specific plasmablasts appear transiently in peripheral blood after vaccination with influenza or other vaccines (Brokstad et al., 1995; Bernasconi et al., 2002; Sasaki et al., 2007; Wrammert et al., 2008), but the kinetics of their appearance and persistence during an ongoing infection remain unclear. Here, we have analyzed the magnitude and specificity of the plasmablast response in blood samples taken within weeks after onset of clinical symptoms of pandemic H1N1 influenza virus infection. Using a virus-specific ELISPOT assay, it was possible to show a significant number of pandemic H1N1-reactive plasmablasts in the blood of the infected patients, whereas none were detectable in a cohort of healthy volunteers (Fig. 1, A and B). These cells were also readily detectable several weeks after symptom onset in the more severe cases. Fig. 1 (A and C) illustrates that, of the total IgG-secreting cells, over half of the cells were producing antibodies that bound pandemic H1N1 influenza virus. Moreover, plasmablasts specific for HA occurred at 30–50% the frequency of virus-specific cells (Fig. 1, C and D), the specificity most likely to be critical for protection. Most patients also had a relatively high frequency of plasmablasts, forming antibodies that bound to past, seasonal influenza strains (Fig. 1 C) or recombinant HA from the previous annual H1N1 strain, A/Brisbane/59/2007. Based on the overall frequency of pandemic H1N1-specific cells, it is likely that the cells binding other strains were overlapping populations and cross-reactive. None of the induced plasmablast cells bound to recombinant HA from the H3N2 strain from the same vaccine (A/Brisbane/10/2007). These findings demonstrate that influenza-specific human plasmablasts are continuously generated throughout an ongoing infection and that a fairly high proportion of these cells make antibodies that also cross-react with previous annual H1N1 influenza strains.

To analyze the specificity, breadth, and neutralizing capacity of these plasmablasts, we used single-cell PCR to amplify the heavy and light chain variable region genes from individually

sorted cells (defined as CD19⁺, CD20^{lo/-}, CD3⁻, CD38^{high}, CD27^{high} cells; Fig. 1 E; Wrammert et al., 2008; Smith et al., 2009). These genes were cloned and expressed as mAbs in 293 cells, and the antibodies were screened for reactivity by ELISA. Thresholds for scoring antibodies as specific to the influenza antigens were empirically determined based on being two standard deviations greater than the background level of binding evident from 48 naive B cell antibodies (Fig. S1 A). Of 86 antibodies generated in this fashion, 46 (53%) bound pandemic H1N1 (Fig. 1 F) and one third (15 antibodies) were reactive to HA (Fig. 1 G and Fig. S2 A), most of them at sub-nanomolar avidities (based on surface plasmon resonance analyses; Fig. S2 B). On a per donor basis, 55% of the mAbs bound to purified pandemic H1N1 virions (range: 33 to 77%). Of the virus-specific antibodies, 31% bound to recombinant HA (range: 14 to 55%). We conclude that virus-specific plasmablasts are readily detected after pandemic H1N1 influenza virus infection and that virus-specific human mAbs can be efficiently generated from these cells.

Plasmablasts from patients infected with pandemic H1N1 influenza were highly cross-reactive to prepandemic influenza strains
As the plasmablasts are specifically induced by the ongoing immune response, we can learn about the origin of the B cells

activated by pandemic H1N1 infection. Consistent with the frequency of plasmablasts secreting antibodies binding annual influenza strains by ELISPOT analyses (Fig. 1 C), a majority (29/46, or 63%) of the pandemic H1N1-specific antibodies also cross-reacted with seasonal influenza viruses (Fig. 2, A and B). In fact, by ELISA, one third of these antibodies bind to the prepandemic strains at lower concentrations than they did to the pandemic H1N1 strain, suggesting higher avidity binding. By comparison, only 22% (11/50) of plasmablasts induced by annual H1N1 strains before the pandemic could bind the pandemic H1N1 influenza (Fig. S1 B). We propose that the cross-reactivity of pandemic H1N1-induced cells derives from the activation of memory cells originally specific for past influenza immunizations in an original antigenic sin fashion.

Evidence of extensive affinity maturation suggests a high frequency of memory cell activation against the pandemic H1N1 strain
Based on the 10–15-fold induction of plasmablasts and expression of intracellular Ki67 during ongoing immune responses (Brokstad et al., 1995; Bernasconi et al., 2002; Sasaki et al., 2007; Smith et al., 2009; Wrammert et al., 2008), we can assume that most plasmablasts result from the ongoing infection

Table I. Summary of clinical data for patients with acute pandemic H1N1 virus infections

Patient	Age	Gender	HAI titer	MN titer	Co-morbidities	Initial symptoms	Hospital course	Sample collection	Antiviral treatment	mAb
EM	30	F	640	1280	none	Fever, cough, dyspnea	Acute respiratory distress syndrome, bacterial pneumonia, pulmonary embolism, prolonged oscillatory ventilator support, tracheostomy, discharged after 2 mo	Day 31	Oseltamivir	Yes
1000	37	M	80	40	Hypertension, interstitial lung disease of unknown etiology	Fever, cough, shortness of breadth, nausea, vomiting	Pneumonia, acute sinusitis, acute renal failure, discharged after 8 d	Day 18	Oseltamivir, Zanamavir	Yes
70	38	F	80	160	none	Fever, cough, body aches	N/A	Day 15	None	Yes
1009	21	M	20	20	Congenital heart disease, repair for Tetralogy of Fallot	Fever, cough, sore throat, nausea, diarrhea	N/A	Day 9	Oseltamivir	Yes
1010	24	M	10	10	none	Fever, cough, nausea, vomiting diarrhea	N/A	Day 11	Oseltamivir	No
1011	25	M	20	10	none	Fever, cough, sore throat, vomiting, headache, confusion	N/A	Day 9	Oseltamivir	No
1013	26	M	80	160	none	Fever, cough, sore throat, body aches, nausea, vomiting, diarrhea	N/A	Day 9	None	No
1014	45	F	80	20	none	Fever, chills, cough, sore throat, body aches, headache, nausea, vomiting	N/A	Day 9	None	No

The mAb column indicates whether mAbs were made from the plasmablasts of these patients.




Figure 1. Generation of human mAbs against pandemic H1N1 influenza virus from infected patients. (A and B) Magnitude of the plasmablast response observed in peripheral blood of six pandemic H1N1-infected patients and 22 healthy (noninfected/nonvaccinated) donors by ELISPOT analysis. (A) Representative ELISPOT. Numbers of plasmablasts secreting antibody reactive to pandemic H1N1 is compared with the total number of IgG-secreting cells from each PBMC sample (numerals). All ELISPOT assays were performed in duplicate. (B) Summary of all the donors analyzed; each dot represents one patient or control. (C and D) Specificity of the sorted plasmablasts measured by ELISPOT analysis. Representative ELISPOT showing plasmablasts producing antibodies reactive with total IgG or pandemic H1N1 whole virus, annual influenza vaccine (2009/2010 TIV vaccine), or recombinant HA from pandemic H1N1, the previous year's annual vaccine H1N1 strain (A/Brisbane/59/2007), or the previous years H3N2 strain (A/Brisbane/10/2007). (D) Summary of the frequency of whole IgG secreting cells specific to pandemic H1N1 whole virus, recombinant HA from pandemic H1N1, and recombinant HA from the previous year's vaccine. Donors EM1 and SF1000 were not analyzed in this fashion, as the antigens were not available for live-cell analyses at that time point in the pandemic. (E) Sorting of plasmablast cells from pandemic H1N1 influenza-infected patients to generate mAbs. Flow cytometry plots show the percentage of CD27^{hi}CD38^{hi} cells (dot plots are gated on CD3⁺CD20^{lo/-} lymphocytes). The plasmablasts are defined herein as CD3⁺CD20^{lo/-}CD19⁺CD38^{hi}CD27^{hi} cells. (right) An example of post-sort purity of ungated cells (verified for each sample). Single plasmablasts were isolated from the sorted fraction by cell sorting, and variable antibody genes were cloned from individual cells (see Materials and methods). (F and G) Scatchard plots of binding of the isolated mAbs to pandemic H1N1 whole-purified virus (F) and pandemic H1N1 recombinant HA (G) as measured by ELISA. Antibodies were scored positive (frequency above plots) if they bound at least two standard deviations greater than the mean absorbance of naive B cell antibodies at 10 μ g/ml (detailed in Fig. S1 A).




Figure 2. Plasmablasts induced by pandemic H1N1 infection are highly cross-reactive and have accumulated particularly high levels of variable gene somatic hypermutation. (A and B) Pandemic H1N1 reactive mAbs isolated from infected patients (1000, EM, 70, 1009) were assayed for binding to annual H1N1 influenza strain whole virus. The minimum detectable concentration is defined as two standard deviations above the mean binding of 48 randomly chosen naive B cell antibodies (Fig. S1 A). Bars are color coded to approximate levels of cross-reactivity to the annual vaccine (circulating) strains of recent years. Panels A and B use the same color scheme. Each value is representative of at least two replicate ELISAs repeated until a single consistent minimum concentration was established. The center numeral equals total antibodies. (C) Analysis of the variable gene sequences from plasmablasts of the four pandemic H1N1-infected patients indicated that ~16.5% of the pandemic H1N1-induced plasmablasts were clonally related (shared identical VH and JH genes and CDR3 junctions). (D) The average number of somatic hypermutations in the pandemic H1N1 patient plasmablast variable region

genes compared with primary IgG plasmablast responses to vaccinia (small pox) or the anthrax vaccine, or after at least 4 boosters with the anthrax vaccine. To account for the obvious outlier in the pandemic H1N1 group (patient-EM), median values are indicated by the bar. Student's *t* tests excluding the outlier indicated a *p*-value of <0.04 for the remaining five pandemic H1N1 samples compared with the IgG memory and germinal center (GC) cells or the primary IgG plasmablast responses (0.2 with EM included) and a *p*-value of <0.0001 against the IgM populations. Notably, besides patient EM, each individual set of VH genes averaged significantly more mutations than the IgG memory and GC or the primary responses (Fig. S3 A). Each point represents one individual donor and is averaged from 25–75 sequences, except for the primary response to anthrax from which only 10 VH genes could be cloned from single cells because of the highly limited response. Mutations accumulated per individual sequence are depicted in Fig. S3. Detailed sequence characteristics are provided in Tables S1–S3. The naive, IgG and IgM GC and memory populations are derived from historical data (Zheng et al., 2004, 2005; Koelsch et al., 2007; Wrammert et al., 2008).

or vaccine response. The ready detection of clonal expansions at a mean frequency of 16.5% of the cells for the six patients supports this view (based on CDR3 sequence similarity; Fig. 2 C). Since the discovery of somatic mutation, it has been appreciated that mutations progressively accumulate on variable genes after repeated immunizations (McKean et al., 1984). Thus, we can gain insight into the origin of the pandemic H1N1 response by comparing the somatic mutation frequency of the plasmablasts present during H1N1 infection to that of other plasmablast responses. The PCR strategy allowed isolation of either IgG or IgA transcripts and identified 68% IgG and 32% IgA plasmablasts from the patients. Similar to plasmablasts induced by annual vaccination (Wrammert et al., 2008), or after a fourth booster vaccine to anthrax, the variable genes of novel H1N1-induced cells from five of the six patients harbored high numbers of somatic mutations

(averaging >19 per patient; Fig. 2 D and Fig. S3 A). For these 5 patients, mutations had accumulated significantly more than from primary IgG plasmablast responses to anthrax or vaccinia (small pox) vaccines, and more so than for IgG-positive memory B cells from our historical data that averaged 14/VH gene (Student's *t* test *P* < 0.05; Zheng et al., 2004, 2005; Koelsch et al., 2007; Wrammert et al., 2008; Fig. 2 C and Fig. S3 B) or from 347 IgG memory cell sequences previously published by another group (averaging 15/VH gene; de Wildt et al., 2000). Interestingly, for patient EM (outlier in Fig. 2 D) who had the most severe infection (Table I), mutations had accumulated at a significantly lower frequency than the IgG controls (Fig. S3 A; *P* < 0.0001), suggesting a unique circumstance such as a low-level or lacking primary response. Detailed sequence characteristics for pandemic H1N1-induced plasmablasts are provided in Tables S1–S3. Though based on a limited

Antibodies were tested at 10 µg/ml and threefold serial dilutions until a nonbinding concentration was determined. Each antibody was tested in at least two (and typically more) replicates for specificity and affinity estimations. Note that only 14 of 15 HA-binding antibodies have curves in G because one of the HA-reactive antibodies only binds HA on whole virions, not on the recombinant protein.

number of patients, the frequent cross-reactivity and high number of somatic mutations support a model in which many of the plasmablasts induced by pandemic H1N1 infection arose from cross-reacting memory B cells.

A majority of the neutralizing antibodies bound to highly conserved epitopes in both the HA stalk and head regions

A high frequency of the HA-specific antibodies was able to neutralize the virus in vitro (totaling 73% or 11/15; Fig. 3 A). These neutralizing antibodies could be further categorized into two distinct groups: (a) neutralizing antibodies that displayed hemagglutination inhibition (HAI) activity (HAI⁺) and (b) neutralizing antibodies that had no HAI activity,

indicating that they bound to sites other than the HA active site. Interestingly, antibodies of the latter type were predominant in the response (Fig. 3 A). This specificity is reminiscent of antibodies against the recently discovered broadly neutralizing epitopes found on the HA stalk, rather than those located on the HA globular head that is more typical for neutralizing antibodies (Ekiert et al., 2009; Sui et al., 2009). Importantly, five of these antibodies are indeed of similar specificity (including antibodies 70-5B03, 70-1F02, 1000-3D04, and a clonal pair from donor 1009: 3B05 and 3E06). These five antibodies bind with high affinity to most H1 strains including all from the vaccines of the past 10 yr, the 1918 pandemic strain, and to the H5 of a highly pathogenic




Figure 3. HA-specific antibodies induced by pandemic H1N1 infection bind cross-reactive neutralizing epitopes. (A) In vitro functional analysis of 15 antibodies from indicated patients that bound pandemic H1N1 influenza recombinant HA protein. The left panel shows HAI minimum effective antibody concentration, the middle panel shows PRNT50 plaque reduction neutralization minimum effective antibody concentration, and the right panel shows ELISA binding summarized as minimum positive concentration (as defined for Fig. 2) against recombinant HA (original curves are in Fig. 1 F and Fig. S2 A). The antibodies are grouped based on whether they show HAI and/or neutralizing (neut) function. Antibody 1009-3B06 was only tested for binding to whole virus, as this antibody did not bind to rHA due to binding of a quaternary or conformationally sensitive epitope that is not present in the recombinant protein. HAI and neutralization assays were performed in duplicate and repeated at least three times. ELISA curves are provided in Fig. S2 A. (B) ELISA binding as shown by minimum positive concentration (defined for Fig. 2) of neutralizing mAbs to rHA or whole virions from pandemic H1N1 or other influenza strains (ELISA binding curves are provided in Fig. S2 A). Three binding patterns (epitopes 1 and 2, and 3) were observed that coincided with specificity comparisons by competitive ELISA, as illustrated in Fig. 4 A. (C) Three representative neutralizing antibodies (EM-4C04, 70-1F02, and 1009-3B06) were used for HAI and microneutralization (MN) activity against pandemic H1N1 and several other annual or laboratory H1N1 influenza strains. Experiments were performed in duplicates and repeated at least three times. Minimum effective concentration is shown for both assays.

avian influenza strain (Fig. 3 B and Fig. S2 A). In addition, these five antibodies cross-compete for a similar epitope that was not over-lapping with the HAI⁺ antibodies (Fig. 4 A, epitope-1). These antibodies are competitively inhibited by a commercial antibody referred to as C179 that binds this HA stalk region (Okuno et al., 1993), and four of five of these antibodies are encoded by the hallmark VH1-69 gene (Ekiert et al., 2009; Sui et al., 2009). To verify HA stalk reactivity, these five antibodies were tested for binding to H5 variants predicted to affect the stalk epitope by the crystal structure, and their binding patterns were compared with that of the prototypical stalk antibody (mAb F10; Sui et al., 2009; Fig. 4 B). Each H5 variant has a single residue mutation in the stalk region and was transiently expressed on 293T cells.

FACS analysis showed that the five antibodies bound to all 13 H5 variants tested at levels quite similar to F10, for which a crystal structure had been generated to define this epitope. Thus, half of the neutralizing and a surprising 10% of all antibodies induced by pandemic H1N1 infection bound to a conserved, critical epitope on the HA stalk. By comparison, none of 50 H1N1 strain-specific antibodies that we had previously isolated after annual vaccination before the 2009 pandemic had this reactivity (unpublished data). The frequency of pandemic-induced, stem-reactive antibodies (5/46) versus those from annual vaccine (0/50) is significantly greater (Chi-square test, $P = 0.02$). Further, this specificity is only rarely seen in human memory B cells (Corti et al., 2010) or from phage-display libraries (Sui et al., 2009). These observations support




Figure 4. The neutralizing antibodies bind to three nonoverlapping epitopes in either the stalk or the globular head of the HA molecule.

(A) Competition ELISA assays were used to determine the similarity in specificity between the various neutralizing antibodies. Shown is the percentage of competition of each antibody in an ELISA binding assay against all other neutralizing antibodies. A 10-fold molar excess of unlabeled antibody was used to inhibit a biotinylated antibody. Percent competition is calculated as the reduction in absorbance relative to the level of inhibition of any particular antibody against itself. Colors indicate degree of inhibition of antibody binding, as indicated. Antibody C179 is a commercial antibody that binds to the stalk region of the HA molecule identifying epitope-1. Epitope-2 and -3 are each on the HA-head active site. 1000-2G06 and the nonneutralizing, but HA-binding, antibodies had no competition with any of the other HA-reactive antibodies and are therefore not shown. VH gene usage of the individual antibodies is listed on the right. All assays were performed in duplicate. (B) Plasmids encoding full-length WT H5-TH04 (A/Thailand/2-SP-33/2004 [H5N1]) and its mutants were transiently transfected into 293T cells. 24 h after transfection, cells were harvested for FACS analysis, and binding of indicated antibodies was tested at 10 μ g/ml. The cell surface HA expression of each of the mutants were verified with a ferret anti-H5N1 serum (not depicted). Antibody F10 was one of the antibodies used to characterize the HA stalk epitope by x-ray crystallography (Sui et al., 2009) and served as a positive control for the binding pattern expected of HA stalk-reactive antibodies to these HA mutants.

the idea that a vaccine might be developed that preferentially targets the HA stalk, thus providing broad protection against many influenza strains.

The remaining neutralizing antibodies were HAI⁺ and therefore bound to the HA globular head. Based on cross-competition analyses, these antibodies fell into two groups binding nonoverlapping regions of the HA head, including epitope-2 and epitope-3 (Fig. 3 B and Fig. 4 A). Indeed, using spontaneous escape mutant selection, we found that the EM4C04 mAb binds to the Sa region of the HA globular head (unpublished data). Thus, by proximity based on the competition assay (Fig. 4 A), we can predict that all of the epitope-2 antibodies bind near the Sa/Sb region (including EM-4C04, 1009-3B06, and 1009-3F01).

Broadly reactive antibodies binding both pandemic H1N1 strains and common annual H1N1 strains have been identified both in humans (Krause et al. 2010; Xu et al., 2010) and in mice (Manicassamy et al., 2010). It is notable that three of five of the HA globular-head-binding antibodies induced by pandemic H1N1 infection were also broadly reactive to various H1N1 strains (Fig. 3 B). One such novel antibody was the SF1009-3B06 antibody that reacts strongly with the pandemic H1N1 strain, as well as all recent H1N1 vaccine strains (Fig. 3 B and Fig. S2 A). The precise epitope to which the 1009-3B06 antibody binds appears to be quite unique; it is only accessible on whole virions, not on recombinant HA, suggesting that the epitope is quaternary in nature. Finally, two antibodies cross-reacted and inhibited hemagglutination

to all recent H1 vaccine strains and reacted strongly to the 1918 pandemic strain (antibodies 1009-3E04 and 1000-3E01; Fig. 3 B and Fig. 4 A, epitope-3). These mAbs bind to past vaccine strains with higher avidity than to the pandemic H1N1. Further studies are underway to precisely identify the epitopes of all neutralizing antibodies in this study.

Only two of 11 neutralizing antibodies were highly specific for the pandemic H1N1 strain alone (Fig. 3 B and Fig. S2 A), including a low avidity antibody, 1000-2G06, which only showed slight neutralization capacity in vitro, and EM-4C04, which was very effective at neutralizing the pandemic H1N1 influenza. We conclude from these experiments that a surprising 82% (9/11) of the neutralizing plasmablasts that we isolated during pandemic H1N1 influenza infections were broadly cross-reactive to multiple influenza strains.

Potent in vivo protection and rescue of mice challenged with a lethal dose of pandemic H1N1 or antigenically distinct influenza virus strains

There is a distinct interest in developing monoclonal antibodies for use in a therapeutic setting. We selected three representative antibodies of the set we have identified for detailed functional analysis both in vitro (Fig. 3 C) and in vivo (Fig. 5 and Fig. 6), including: EM-4C04, 1009-3B06, and 70-1F02. The antibodies EM-4C04 and 1009-3B06 are specific for the active site of the HA molecule, whereas 70-1F02 binds to the stalk region. Furthermore, EM-4C04 is highly specific for pandemic H1N1, whereas 1009-3B06 and 70-F02 display




Figure 5. In vivo prophylactic and therapeutic efficacy of human mAbs against pandemic H1N1 influenza virus. 6–8-wk-old BALB/c mice were infected with a 3xLD50 dose of highly pathogenic, mouse-adapted 2009 pandemic H1N1 influenza (A/California/04/09). 24, 48, and 60 h after infection, 200 μ g (10 mg/kg of body weight) of EM-4C04, 70-F02, or 1009-3B06 human mAb were injected intraperitoneally. All mice were monitored daily for body weight changes and any signs of morbidity and mortality. Percentage of initial body weight is plotted, and the number of surviving mice is shown in the lower right of each plot. Infected, untreated mice showed clear signs of sickness around day 4–5 after infection and perished by day 8–9. Prophylactic treatment is shown on the left for comparison. Antibody treatment conferred significant protection as determined by comparison of weights in untreated versus prophylaxis and at the time of treatment versus 12 d after infection (unpaired, two-tailed Student's *t* test, *P* < 0.05). The log-rank test indicated significant survival as well (*P* < 0.001). Figure shows one representative experiments of at least three independent repeat experiments.




Figure 6. Breadth of in vivo prophylactic efficacy in mice. 6–8-wk-old BALB/c mice were treated with 200 μ g (10 mg/kg of body weight) EM-4C04, 70-1F02, or 1009-3B06 human mAb intraperitoneally. Control mice were treated with PBS only, a control mAb or polyclonal human IgG. 12 h later, they were challenged with a 3xLD₅₀ dose of mouse adapted pandemic H1N1, PR/8/34, or FM/1/47 influenza virus. All mice were monitored daily for body weight changes and any signs of morbidity and mortality. Percentage of initial body weight (left) and survival curves (right) are plotted. Infected, untreated mice showed clear signs of sickness ~4–5 d after infection and perished by day 8–9. Figure shows one representative experiments of at least three independent repeat experiments. Antibody treatment conferred significant protection as determined by comparison of weights in untreated versus prophylaxis, and at the time of treatment versus 12 d after infection (unpaired, two-tailed Student's *t* test, *P* < 0.05). The log-rank test indicated significant survival as well (*P* < 0.003).

broadly cross-reactive binding (Fig. 3 B) and have functional activity against multiple recent and older H1N1 strains (Fig. 3 C). These antibodies were all highly effective at providing prophylactic protection against infection with a lethal dose of mouse-adapted pandemic H1N1 in 6–8-wk-old BALB/c mice (Fig. 5). Moreover, all three antibodies were effective therapeutically, even when they were administered as late as 60 h after the lethal challenge infection, well after the mice were symptomatic. For EM-4C04, we have successfully treated mice as far out as 72 h post-infection (unpublished data). Infected mice were already showing measurable weight loss that was reversed by administration of the antibody, demonstrating therapeutic potential even after the onset of disease. Viral clearance was analyzed in mice treated at 48 h after infection with EM4C04 (Fig. S4). As early as day 4, the antibody-treated mice exhibited more than a log reduction in viral titers; titers continued to decline, such that by day 6, virus was undetectable or present at very low levels. The untreated mice perished by day 7 or 8, whereas the treated mice cleared the infection with no detectable virus on day 12. Finally, 1009-3B06 and 70-1F02, which showed activity against several current and older H1N1 seasonal influenza strains *in vitro* (Fig. 3 C), were also tested *in vivo* against antigenically distinct influenza strains. For these experiments, mice were treated with 200 μ g of mAb intraperitoneally 12 h before infection with a lethal dose of either pandemic H1N1 influenza or either of the two common influenza laboratory strains PR/8/34 or FM/1/47. 1009-3B06 and 70-1F02 showed protection against these antigenically distinct H1N1 influenza strains, as illustrated in Fig. 5. EM-4C04, which is highly specific

for the pandemic H1N1, had no protective effect on infection with PR/8/34 or FM/1/47. In conclusion, the antibodies characterized herein show promise for development as broadly reactive therapeutic agents against the pandemic H1N1 influenza virus, as well as against the majority of H1N1 and H5N1 influenza strains.

DISCUSSION

Our findings provide insight into the human B cell responses to a pandemic influenza virus strain. The unique genetic composition of the pandemic H1N1 influenza virus meant that our relatively young cohort probably had little or no pre-existing specific antibody-mediated immunity to this virus before infection (Brockwell-Staats et al., 2009; Dawood et al., 2009; Garten et al., 2009; Hancock et al., 2009). Thus, two sources of B cells could have contributed to this response: newly recruited naive B cells and preexisting memory B cells that bound to epitopes conserved between past seasonal strains and the pandemic H1N1 strain. We theorize that predominant activation of the latter, preexisting memory cells can account for the observed high frequency of neutralizing antibodies (11/15 HA-binding antibodies), the majority (9/11) of which are cross-reactive with seasonal H1N1 strains (Fig. 3 C) and other group 1 influenza strains, including H5 HA. Several observations support this conjecture.

Most convincingly, there was a particularly high frequency of cross-reactive antibodies overall, with a high level of somatic mutations found particularly among the variable genes of cross-reacting cells (Fig. 2 and Fig. S3). In fact, by ELISA most antibodies were cross-reactive and one third of the

antibodies bound to past annual viral antigens at lower concentrations, suggesting higher avidity to past influenza strains than to the current pandemic H1N1 virus. Further, cross-reacting cells that bind with higher affinity to the pandemic H1N1 strain also have the highest frequency of variable-gene mutations (Fig. S3 B). Antibodies that were broadly cross-reactive were among the more highly mutated clones (Fig. S3 B). We propose that many of these cells were specific for cross-reactive epitopes present in annual influenza strains that then underwent further affinity maturation and adaptation to the infecting pandemic H1N1 virus. Supporting this conjecture, Corti et al. (2010) first demonstrated that naturally occurring HA stalk-reactive memory B cells could be isolated from the blood of people recently immunized with the annual vaccine, before the outbreak of pandemic H1N1. The nature of that study was to screen EBV-transformed memory cell lines, thus precluding the determination of precise frequencies of these stalk-reactive B cells. However, these antibodies were estimated to be quite rare; occurring at one in thousands to one in hundreds of influenza-binding B cells, varying by individual. In contrast, we show that plasmablasts activated by infection with the highly novel pandemic H1N1 influenza strain have substantially increased targeting to the HA stalk region epitopes, totaling 10% of all influenza-specific antibodies and half of the neutralizing antibodies (Fig. 4). In fact, most specific antibodies isolated in this study were cross-reactive to past influenza strains. Collectively, the data described supports a model in which divergent viruses that are conserved only at the most critical regions for function will elicit a higher proportion of cross-reactive and neutralizing antibodies. Thus, although the activated plasmablasts of relatively few patients could be analyzed in detail at the monoclonal antibody level, we proffer that with the proper immunogen, the long-sought development of a pan-influenza vaccine might be possible.

Interestingly, the highly specific antibody EM-4C04 was derived from a patient that had a very severe disease course, with persistent viral shedding over several weeks. In addition, the variable genes from the plasmablasts of this patient had the lowest average number of somatic mutations (Fig. 2 B, outlier, and Fig. S3 B). Collectively, the unique specificity against pandemic H1N1, the low levels of somatic mutation, and the unusually severe disease in the absence of predisposing conditions suggest that this patient may have mounted a primary immune response to the pandemic H1N1 influenza infection. The complete lack of preexisting immunity may have contributed to the more severe disease observed in this patient. In contrast, the activation of broadly cross-neutralizing memory B cells in those with immune experience to annual strains might have contributed to the less severe disease of most infected patients during the pandemic.

It is notable that there is a discrepancy between patients for serum MN titers, the severity of disease, and the frequency of plasmablasts expressing neutralizing antibodies (Table I and Fig. 3). For example, patient EM, despite having the worst disease course, had the greatest HAI and MN serum titers. This may be caused by the time from infection (day 31), allowing full

seroconversion, or by the presence of highly potent antibodies, such as EM-4C04, whose activities were less likely to titer out. The highly specific nature of the response from this patient may have contributed to this advantage, ultimately better targeting the epitopes of the pandemic H1N1 strain. In contrast, patient 1009 had relatively low HAI and MN serum titers but the highest frequency of broadly neutralizing antibodies and a less severe disease course. One possibility is that our sampling from this patient was done before peak serological responses. Another possibility is that the high frequency of these potent antibodies in the memory B cell compartment may have resulted in rapid resolution of infection, precluding the development of a high serological response. A third possibility is that despite broader protection, the stalk-reactive antibodies are on the whole less potent and more rapidly titrated out than the highly specific antibodies to the HA globular head. These various possibilities will be of significant interest to study in the future.

Finally, we report the development of a large panel of human mAbs induced by pandemic H1N1 infection. Prophylactic therapy with polyclonal or mAbs has successfully been used for RSV, rabies, Hepatitis A and B, and varicella. In the case of influenza, mAbs have been shown to provide prophylactic or therapeutic protection in mice and other animal models (Reuman et al., 1983; Sweet et al., 1987; Palladino et al., 1995; Renegar et al., 2004). Passive transfer of maternal antibodies in humans has also been shown to confer protection (Puck et al., 1980). Several of the antibodies we isolated have broad neutralization capacity *in vitro* against divergent influenza strains and show potent prophylactic and therapeutic activity when used to treat mice that were lethally infected with influenza. These antibodies could provide much needed pandemic therapeutics to treat severe cases of influenza and to protect high-risk populations.

In conclusion, analyses of the 46 mAbs induced by pandemic H1N1 infection indicated frequent activation of broadly reactive B cells. We propose that these cells had a memory cell origin caused by cross-reactivity to conserved and functionally important epitopes. If true, it will be important to characterize the efficacy of the pandemic H1N1 vaccine to induce a similarly cross-protective response.

MATERIALS AND METHODS

Patients. All studies were approved by the Emory University, University of Chicago, and Columbia University institutional review boards (Emory IRB#22371 and 555-2000, U of C IRB# 16851E, CU IRB#AAAE1819). Patient clinical information is detailed in Table I.

PBMC and plasma isolation. All work with samples from infected patients was performed in a designated BSL2⁺ facility at Emory University. Peripheral blood mononuclear cells (PBMCs) were isolated using Vacutainer tubes (BD), washed, and resuspended in PBS with 2% FCS for immediate use or frozen for subsequent analysis. Plasma samples were saved at -80°C or frozen in medium with 10% dimethyl sulfoxide for subsequent analysis.

Viruses and antigens. The pandemic H1N1 influenza virus (A/California/04/2009) was provided by R.J. Webby (St. Jude Childrens Hospital, Memphis, TN). Influenza virus stocks used for the assays were freshly grown in eggs,

prepared, and purified as previously described (Wrammert et al., 2008). The hemagglutination inhibition activity was determined using turkey red blood cells (Lampire Biological Laboratories) as previously described (Wrammert et al., 2008) or purchased as inactivated preparations (ProSpec-Tany TechnoGene Ltd.) which included the following: A/California/04/09 (H1N1), A/FM/1/47 (H1N1), A/PR8/34 (H1N1), A/New Caledonia/20/99 (H1N1), A/Solomon Island/3/06, A/Brisbane/59/07 (H1N1), and A/Brisbane/10/07 (H3N2). Vaccines tested included the 2006/7 vaccine from Chiron Vaccines Limited and the 2008/9 formulation from Sanofi Pasteur Inc. Recombinant HA proteins were provided by the influenza reagent resource (www.influenzareagentresource.org) of the CDC (recombinant HA from A/California/04/2009 [H1N1; #FR-180], A/Brisbane/10/2007 [H1N1; #FR-61], A/Brisbane/59/2007 [H3N2; #FR-65]) or by Biodefense and Emerging Infections research repository (www.beiresources.org; recombinant HA from A/Indonesia/05/2005 [H5N1]). A/Brevig Mission/1/1918 (H1N1) was purchased from Sino Biological.

ELISPOT assay. Direct ELISPOT to enumerate the number of either total IgG-secreting, pandemic H1N1 influenza-specific, or vaccine-specific plasmablasts present in the PBMC samples were essentially done as previously described (Crotty et al., 2003). In brief, 96-well ELISPOT filter plates (Millipore) were coated overnight with either the optimized amounts of purified pandemic H1N1 virions, recombinant HA from the pandemic H1N1 (as above), the 08/09 influenza vaccine at a dilution of 1/20 in PBS, or goat anti-human Ig (Invitrogen). Plates were washed and blocked by incubation with RPMI containing 10% FCS at 37°C for 2 h. Purified and extensively washed PBMCs or sorted plasmablasts were added to the plates in dilution series and incubated for 6 h. Plates were washed with PBS, followed by PBS containing 0.05% Tween, and then incubated with a biotinylated anti-huIgG (γ) antibody (Invitrogen) and incubated for 1.5 h at room temperature. After washing, the plates were incubated with an avidin-D-HRP conjugate (Vector Laboratories) and, finally, developed using AEC substrate (3 amino-9 ethyl-carbazole; Sigma-Aldrich). Developed plates were scanned and analyzed using an automated ELISPOT counter (Cellular Technologies, Ltd.).

Flow cytometry analysis and cell sorting. Analytical flow cytometry analysis was performed on whole blood after lysis of erythrocytes and fixing in 2% PFA. All live cell sorting and single cell sorting was performed on purified PBMCs using either a FACS Vantage or ARIAII cell sorter system. All of the following antibodies for both analytical and cell sorting cytometry were purchased from BD, except anti-CD27, which was purchased from eBioscience: anti-CD3-PECy7 or PerCP, anti-CD20-PECy7 or PerCP, anti-CD38-PE, anti-CD27-APC, and anti-CD19-FITC. ASCs were gated and isolated as CD19⁺CD3⁺CD20^{lo}CD27^{high}CD38^{high} cells. Flow cytometry data were analyzed using FlowJo software.

Generation of mAbs. Identification of antibody variable region genes were done essentially as previously described (Smith et al., 2009; Wardemann et al., 2003; Wrammert et al., 2008). In brief, single ASCs were sorted into 96-well PCR plates containing RNase inhibitor (Promega). VH and V κ genes from each cell were amplified by RT-PCR and nested PCR reactions using cocktails of primers specific for both IgG and IgA using primer sets detailed in (Smith et al., 2009) and then sequenced. To generate recombinant antibodies, restriction sites were incorporated by PCR with primers to the particular variable and junctional genes. VH or V κ genes amplified from each single cell were cloned into IgG1 or Ig κ expression vectors, as previously described (Wardemann et al., 2003; Wrammert et al., 2008; Smith et al., 2009). Antibody sequences are deposited on GenBank (accession nos. HQ689701-HQ689792 available from GenBank/EMBL/DBJ). Heavy/light chain plasmids were cotransfected into the 293A cell line for expression and antibodies purified with protein a sepharose. Antibody proteins generated in this study can be provided in limited quantities upon request.

Mutational analysis. Antibody anti-H1N1 induced plasmablast variable genes were amplified by single-cell RT-PCR using primer sets and PCR

conditions that were previously published (Wrammert et al., 2008; Smith et al., 2009). Variable genes were determined using in-house analysis software compared with the Immunogenetics V gene dataset and the IMGT search engine (Ehrenmann et al., 2010; Lefranc et al., 2009). Background mutation rates by this method is ~ 1 base-exchange per 1,000 bases sequenced (based on sequences of constant region gene segments). Comparisons were made to historical data, some of which was previously published (Zheng et al., 2005; Wrammert et al., 2008; Duty et al., 2009).

Plaque assay and PRNT₅₀ assay. MDCK cells were grown in 6-well plates at a density of 8×10^5 /well. On the next day, cells were washed with PBS. 10-fold dilutions of virus were added in 500 μ l DME and incubated at 37°C for 1 h, with mixing every 10 min. Cells were washed with PBS and overlaid with 199 media containing 0.5% agarose (Seakem), 1x antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin), 0.2% BSA (Sigma-Aldrich), and 0.5 μ g/ml TPCK-Trypsin (Sigma-Aldrich). Cells were incubated for 36–40 h and fixed with 2% PFA for 10 min. Agarose plugs were removed and cells were stained with 0.1% crystal violet in 25% EtOH for 1 min. After removal from the crystal violet solution, plates were dried and used to count plaques in each well. For PRNT₅₀ assay, MDCK cells were prepared as above. On the next day, mAbs were threefold-diluted (60–0.74 μ g/ml). 100 PFU of virus in 250 μ l DME were incubated with equal volume of diluted mAbs at 37°C for 1 h before the plaque assay. Plaques were counted and the final concentration of antibodies that reduced plaques to <50 PFU were scored as PRNT₅₀.

Determination of 50% tissue culture infectious dose (TCID₅₀) and MN. To determine the TCID₅₀, MDCK cells were grown in 96-well plate at a density of 1.5×10^4 /well. On the next day, cells were washed with PBS and 10-fold diluted viruses in 100 μ l DME were added into each well and incubated at 37°C for 1 h. After the incubation, cells were washed with PBS and 100 μ l of DME containing 1x antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin), 0.5% BSA (Sigma-Aldrich), and 0.5 μ g/ml TPCK-Trypsin (Sigma-Aldrich) was added. Cells were further incubated for 60 h, and 50 μ l of the supernatant was incubated with equal volume of 0.5% of PBS-washed Turkey red blood cells (Rockland Immunochemicals) for 30 min. Four replicates were performed for each dilution, and complete agglutination was scored as HA⁺. Virus titers were calculated by the Reed-Muench method. For MN assay, 100 TCID₅₀ of virus in 50 μ l DME were incubated with 50 μ l of threefold-diluted antibodies (60–0.082 μ g/ml) at 37°C for 1 h. Cells were washed and incubated in the media as described for the HAI assay for 60 h. The MN titer was determined to be the final concentration of mAbs that completely inhibited infection.

HAI and ELISA assays. Whole virus, recombinant HA, or vaccine-specific ELISA was performed on starting concentrations of 10 μ g/ml of virus or recombinant HA and on 1:20 dilution of the vaccine, as previously described (Wrammert et al., 2008). In brief, microtiter plates were coated with live virus strains totaling 8 HAU of total virus per well or with 1 μ g/ml of recombinant HA protein. To standardize the various ELISA assays, common high-affinity antibodies with similar affinities and binding characteristics against each virus strain were included on each plate, and the plate developed when the absorbance of these controls reached 3.0 ± 0.1 OD units. Goat anti-human IgG (goat anti-human I-peroxidase-conjugate; Jackson ImmunoResearch Laboratories) was used to detect binding of the recombinant antibodies, followed by development with horseradish peroxidase substrate (Bio-Rad laboratories). Absorbencies were measured at OD415 on a microplate reader (Invitrogen). Affinity estimates were calculated by nonlinear regression analysis of curves from eight dilutions of antibody (10 to 0.125 μ g/ml) using GraphPad Prism. The HAI titers were determined as previously described (Wrammert et al., 2008). In brief, the samples were then serially diluted with PBS in 96-well v-bottom plates and 8 HAU (as determined by incubation with 0.5% turkey RBCs in the absence of serum) of live, egg-grown virus was added to the well. After 30 min at room temperature, 50 μ l of 0.5% turkey RBCs

(Rockland Immunochemicals) suspended in PBS with 0.5% BSA was added to each well and the plates were shaken manually. After an additional 30 min at room temperature, the serum titers or minimum effective concentrations were read based on the final dilution for which a button was observed.

Competition ELISA. Competition ELISA was performed by inhibiting binding of each biotinylated antibody (NHS-coupled; Thermo Fisher Scientific) at the half-maximal binding concentration with a 10-fold molar excess of purified antibody. All comparisons of different antibodies were based on percentage of absorbance values for each antibody against itself (which was scored as 100% inhibition). Detection was done using streptavidin-HRP as described for the ELISA assay.

FACS analysis of binding of anti-HA antibodies with H5 and its mutants. The full-length HA gene (H5–TH04) of A/Thailand/2(SP-33)/2004 (H5N1) were codon-optimized for eukaryotic cell expression and cloned into pcDNA3.1 vector to obtain the pcDNA3.1–H5–TH04 construct (Sui et al., 2009). All mutants of H5–TH04 were derived from pcDNA3.1–H5–TH04 and constructed by the QuikChange method (Stratagene). The full-length wild type H5–TH04 and mutants expressing plasmids were transfected transiently into 293T cells with Lipofectamine 2000 (Invitrogen). 24 h after transfection, cells were harvested for immunostaining. Anti-HA antibodies, a control human mAb 80R (Sui et al., 2004) at 10 µg/ml, or ferret anti-H5N1 serum at 1:300 dilution were incubated with transfected 293T cells at 4°C for 1 h. Cells were then washed three times with PBS containing 0.5% BSA and 0.02% Na₂S₂O₃. FITC-labeled goat anti-human IgG (Thermo Fisher Scientific) or FITC-labeled goat anti-ferret IgG (Bethyl) were then added to cells and incubated for 30 min at 4°C. Cells were washed as above, and binding of antibodies to cells was analyzed using a BD FACS-Calibur with CellQuest software.

BIACORE analysis. The kinetic interactions of the mAbs with recombinant A/Cal/04/09 (H1N1) HA protein were determined by surface plasmon resonance (SPR) using a Biacore3000 instrument. EM4CO4 and SF1009–3F01 antibodies were immobilized at 10 µl/min^{−1} on a CM5 sensor chip by amine coupling and recombinant HA at concentrations ranging from 0.5 to 15 nM in HBS-EP buffer were injected at 20 µl/min^{−1} over the immobilized antibodies or reference cell surface. Running buffer (HBS-EP) was then applied for 600 s, after which the sensor surface was regenerated by a single injection of 25 mM NaOH at 100 µl/min^{−1}. For the other experiments, recombinant HA (His-tagged) was immobilized at 5 µl/min^{−1} on NTA sensor chips with a target density of 350 response units, and the antibodies at concentrations ranging from 1 to 30 nM in HBS-P buffer were injected at 20 µl/min^{−1} over the immobilized recombinant HA or reference cell surface, followed by a 600 s dissociation phase. All experiments were performed in triplicates. For kinetic analysis, injections over reference cell surface and injections with buffer were subtracted from the data. Association rates (k_a), dissociation rates (k_d) and equilibrium dissociation constants (K_d) were calculated by aligning the curves to fit a 1:1 binding model using BIAevaluation 4.1 software. Antibodies 1009–3B06, 1000–3E01, and 1000–2G06 could not be determined because these mAbs did not bind to the recombinant HA protein from baculovirus sufficiently well for SPR. Avidities for these mAbs and for the antibodies that did not neutralize infection *in vitro* were estimated by Scatchard plot analyses of ELISA data (shown in parentheses).

In vivo protection experiments. 6–8-wk-old female BALB/c mice were used for the challenge studies. Mice were inoculated intranasally with 3xLD50 of a highly pathogenic, mouse-adapted pandemic H1N1 influenza virus (A/California/04/09), or PR/8/34 or FM/1/47 influenza virus. The mouse adapted pandemic H1N1 virus had been serially passaged in mice for five generations before use herein. The LD50 for all the viruses was determined by *in vivo* infection at various virus concentrations, according to the method of Reed and Muench. The experiments were conducted in accordance with ethical procedures and policies approved by the Emory University's Institutional Animal Care and Use Committee. To determine the prophylactic

efficacy of the mAb, mice were treated intraperitoneally with 200 µg (10 mg/kg of body weight) of the specific mAbs. 12 h later, mice were challenged with 3xLD50 of one of the mouse adapted influenza viruses used in the study. All mice were monitored daily for any signs of morbidity and mortality. Body weight changes were registered daily for a period of 14 d. All mice that lost >25% of their initial body weight were sacrificed according to the institutional animal care and use committee guidelines. To determine the therapeutic efficacy of the mAbs, mice were challenged with 3xLD50 of the mouse-adapted pandemic H1N1 virus. At various times after infection (12, 24, 36, 48, 60, and 72 h) mice were treated intraperitoneally with 200 µg (10 mg/kg of body weight) of the specific mAbs. All mice were monitored daily and the body weight changes were registered daily as described above.

Statistical analysis. Data were collected and graphed using MS Excel and GraphPad Prism software. Efficacy of the therapeutic and challenge experiments was evaluated by analysis of variance using GraphPad Prism software.

Online supplemental material. Fig. S1 shows the binding characteristics of control mAbs. Fig. S2 shows further binding characteristics of the neutralizing mAbs. Fig. S3 shows further analysis of pandemic H1N1-induced plasmablast somatic mutations. Fig. S4 shows experiments demonstrating the therapeutic control of pandemic H1N1 viral titers in lungs after mAb treatment. Tables S1–S3 provide detailed characteristics concerning the variable gene sequences cloned from pandemic H1N1 induced plasmablasts. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20101352/DC1>.

We thank Drs. Richard J. Webby and Gillian Air for providing us with viral isolates. We also thank Robert Karaffa and Sommer Durham for providing essential support with cell sorting and Dr. Ruben Donis (CDC) for his generous gift of ferret anti-H5 serum.

This work was funded in parts by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) U19-AI057266 with ARRA supplement funding U19 AI057266–06S2 (R. Ahmed and P.C. Wilson), by NIH/NIAID HHSN266200700006C Center of Excellence for Influenza Research and Surveillance (R. Ahmed, R. Compans, and P.C. Wilson), by the Northeast Biodefense Center U54-AI057158-Lipkin (R. Ahmed, W.I. Lipkin, and P.C. Wilson), by NIH/NIAID HHSN266200500026C (P.C. Wilson), by NIH/NIAID 5U19AI062629–05 (P.C. Wilson), and by NIH/NIAID U01-AI074518 (W.A. Marasco) and the National Foundation for Cancer Research (W.A.M.). J. Wrammert was supported by a training fellowship through the Center of Excellence for Influenza Research and Surveillance and D. Koutsouanos by U01-AI074579 (R. Compans). This research was supported in part by the Intramural Research Program of the NIAID.

The authors declare no financial or commercial conflicts of interest.

Submitted: 6 July 2010

Accepted: 13 December 2010

REFERENCES

- Beigel, J.H. 2008. Influenza. *Crit. Care Med.* 36:2660–2666. doi:10.1097/CCM.0b013e318180b039
- Bernasconi, N.L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. *Science*. 298:2199–2202. doi:10.1126/science.1076071
- Brockwell-Staats, C., R.G. Webster, and R.J. Webby. 2009. Diversity of Influenza Viruses in Swine and the Emergence of a Novel Human Pandemic Influenza A (H1N1). *Influenza Other Respir. Viruses*. 3:207–213. doi:10.1111/j.1750-2659.2009.00096.x
- Brokstad, K.A., R.J. Cox, J. Olofsson, R. Jonsson, and L.R. Haaheim. 1995. Parenteral influenza vaccination induces a rapid systemic and local immune response. *J. Infect. Dis.* 171:198–203.
- Corti, D., A.L. Suguitan Jr., D. Pinna, C. Silacci, B.M. Fernandez-Rodriguez, F. Vanzetta, C. Santos, C.J. Luke, F.J. Torres-Velez, N.J. Temperton, et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. *J. Clin. Invest.* 120:1663–1673.

- Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. *J. Immunol.* 171:4969–4973.
- Dawood, F.S., S. Jain, L. Finelli, M.W. Shaw, S. Lindstrom, R.J. Garten, L.V. Gubareva, X. Xu, C.B. Bridges, and T.M. Uyeki; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. *N. Engl. J. Med.* 360:2605–2615. doi:10.1056/NEJMoa0903810
- de Wildt, R.M., I.M. Tomlinson, W.J. van Venrooij, G. Winter, and R.M. Hoet. 2000. Comparable heavy and light chain pairings in normal and systemic lupus erythematosus IgG(+) B cells. *Eur. J. Immunol.* 30: 254–261. doi:10.1002/1521-4141(200001)30:1<254::AID-IMMU254>3.0.CO;2-X
- Duty, J.A., P. Szodoray, N.Y. Zheng, K.A. Koelsch, Q. Zhang, M. Swiatkowski, M. Mathias, L. Garman, C. Helms, B. Nakken, et al. 2009. Functional energy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. *J. Exp. Med.* 206:139–151. doi:10.1084/jem.20080611
- Ehrenmann, F., Q. Kaas, and M.P. Lefranc. 2010. IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF. *Nucleic Acids Res.* 38(Database issue):D301–D307. doi:10.1093/nar/gkp946
- Ekiert, D.C., G. Bhabha, M.A. Elsliger, R.H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit, and I.A. Wilson. 2009. Antibody recognition of a highly conserved influenza virus epitope. *Science*. 324:246–251. doi:10.1126/science.1171491
- Garten, R.J., C.T. Davis, C.A. Russell, B. Shu, S. Lindstrom, A. Balish, W.M. Sessions, X. Xu, E. Skepner, V. Deyde, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. *Science*. 325:197–201. doi:10.1126/science.1176225
- Gerhard, W., K. Mozdzanowska, M. Furchner, G. Washko, and K. Maiese. 1997. Role of the B-cell response in recovery of mice from primary influenza virus infection. *Immunol. Rev.* 159:95–103. doi:10.1111/j.1600-065X.1997.tb01009.x
- Hancock, K., V. Veguilla, X. Lu, W. Zhong, E.N. Butler, H. Sun, F. Liu, L. Dong, J.R. DeVos, P.M. Gargiullo, et al. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N. Engl. J. Med.* 361:1945–1952. doi:10.1056/NEJMoa0906453
- Koelsch, K., N.-Y. Zheng, Q. Zhang, A. Duty, C. Helms, M.D. Mathias, M. Jared, K. Smith, J.D. Capra, and P.C. Wilson. 2007. Mature B cells class switched to IgD are autoreactive in healthy individuals. *J. Clin. Invest.* 117:1558–1565. doi:10.1172/JCI27628
- Krause, J.C., T.M. Tumpey, C.J. Huffman, P.A. McGraw, M.B. Pearce, T. Tsibane, R. Hai, C.F. Basler, and J.E. Crowe Jr. 2010. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. *J. Virol.* 84:3127–3130. doi:10.1128/JVI.02184-09
- Lefranc, M.P., V. Giudicelli, C. Ginestoux, J. Jabado-Michaloud, G. Folch, F. Bellahcene, Y. Wu, E. Gemrot, X. Brochet, J. Lane, et al. 2009. IMGT, the international ImMunoGeneTics information system. *Nucleic Acids Res.* 37(Database issue):D1006–D1012. doi:10.1093/nar/gkn838
- Luke, T.C., E.M. Kilbane, J.L. Jackson, and S.L. Hoffman. 2006. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann. Intern. Med.* 145:599–609.
- Manicassamy, B., R.A. Medina, R. Hai, T. Tsibane, S. Stertz, E. Nistal-Villán, P. Palese, C.F. Basler, and A. García-Sastre. 2010. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. *PLoS Pathog.* 6:e1000745. doi:10.1371/journal.ppat.1000745
- McKean, D., K. Huppi, M. Bell, L. Staudt, W. Gerhard, and M. Weigert. 1984. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. *Proc. Natl. Acad. Sci. USA*. 81:3180–3184. doi:10.1073/pnas.81.10.3180
- Okuno, Y., Y. Isegawa, F. Sasao, and S. Ueda. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. *J. Virol.* 67:2552–2558.
- Palladino, G., K. Mozdzanowska, G. Washko, and W. Gerhard. 1995. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. *J. Virol.* 69:2075–2081.
- Puck, J.M., W.P. Glezen, A.L. Frank, and H.R. Six. 1980. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. *J. Infect. Dis.* 142:844–849.
- Renegar, K.B., P.A. Small Jr., L.G. Boykins, and P.F. Wright. 2004. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. *J. Immunol.* 173:1978–1986.
- Reuman, P.D., C.M. Paganini, E.M. Ayoub, and P.A. Small Jr. 1983. Maternal-infant transfer of influenza-specific immunity in the mouse. *J. Immunol.* 130:932–936.
- Sasaki, S., M.C. Jaimes, T.H. Holmes, C.L. Dekker, K. Mahmood, G.W. Kemble, A.M. Arvin, and H.B. Greenberg. 2007. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. *J. Virol.* 81:215–228. doi:10.1128/JVI.01957-06
- Simmons, C.P., N.L. Bernasconi, A.L. Suguitan, K. Mills, J.M. Ward, N.V.V. Chau, T.T. Hien, F. Sallusto, Q. Ha, J. Farrar, et al. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. *PLoS Med.* 4:e178. doi:10.1371/journal.pmed.0040178
- Smith, K., L. Garman, J. Wrammert, N.Y. Zheng, J.D. Capra, R. Ahmed, and P.C. Wilson. 2009. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. *Nat. Protoc.* 4:372–384. doi:10.1038/nprot.2009.3
- Steel, J., A.C. Lowen, T. Wang, M. Yondola, Q. Gao, K. Haye, A. Garcia-Sastre, and P. Palese. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. *MBio*. 1:e00018-10.
- Subbarao, K. and T. Joseph. 2007. Scientific barriers to developing vaccines against avian influenza viruses. *Nat. Rev. Immunol.* 7:267–278.
- Sui, J., W. Li, A. Murakami, A. Tamin, L.J. Matthews, S.K. Wong, M.J. Moore, A.S. Tallarico, M. Olurinde, H. Choe, et al. 2004. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. *Proc. Natl. Acad. Sci. USA*. 101:2536–2541. doi:10.1073/pnas.0307140101
- Sui, J., W.C. Hwang, S. Perez, G. Wei, D. Aird, L.M. Chen, E. Santelli, B. Sec, G. Cadwell, M. Ali, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. *Nat. Struct. Mol. Biol.* 16:265–273. doi:10.1038/nsmb.1566
- Sweet, C., R.A. Bird, K. Jakeman, D.M. Coates, and H. Smith. 1987. Production of passive immunity in neonatal ferrets following maternal vaccination with killed influenza A virus vaccines. *Immunology*. 60:83–89.
- Wang, T.T., G.S. Tan, R. Hai, N. Pica, E. Petersen, T.M. Moran, and P. Palese. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. *PLoS Pathog.* 6:e1000796. doi:10.1371/journal.ppat.1000796
- Wardemann, H., S. Yurasov, A. Schaefer, J.W. Young, E. Meffre, and M.C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. *Science*. 301:1374–1377. doi:10.1126/science.1086907
- Wei, C.J., J.C. Boyington, P.M. McTamney, W.P. Kong, M.B. Pearce, L. Xu, H. Andersen, S. Rao, T.M. Tumpey, Z.Y. Yang, and G.J. Nabel. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. *Science*. 329:1060–1064. doi:10.1126/science.1192517
- Wrammert, J., K. Smith, J. Miller, W.A. Langley, K. Kokko, C. Larsen, N.Y. Zheng, I. Mays, L. Garman, C. Helms, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. *Nature*. 453:667–671. doi:10.1038/nature06890
- Xu, R., D.C. Ekiert, J.C. Krause, R. Hai, J.E. Crowe Jr., and I.A. Wilson. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. *Science*. 328:357–360.
- Zheng, N.Y., K. Wilson, X. Wang, A. Boston, G. Kolar, S.M. Jackson, Y.J. Liu, V. Pascual, J.D. Capra, and P.C. Wilson. 2004. Human immunoglobulin selection associated with class switch and possible tolerogenic origins for C delta class-switched B cells. *J. Clin. Invest.* 113:1188–1201.
- Zheng, N.Y., K. Wilson, M. Jared, and P.C. Wilson. 2005. Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation. *J. Exp. Med.* 201:1467–1478. doi:10.1084/jem.20042483

Supplemental table 1: Novel H1N1 Influenza-induced plasmablasts with detectable binding

NAME*	V-GENE	Mutations	V %ID	J-GENE	D-GENE	CDR-lengths	AA JUNCTION
Donor-1000							
1000-1B02H	IGHV3-21	28	90	IGHJ4	IGHD4-17	8.8.14	CARDRYADSNYYFDSW
1000-1B02K	IGKV3-15	8	97	IGKJ4		6.3.10	CQQYSQWPPLTF
1000-1C03H	IGHV3-21	21	93	IGHJ6	IGHD3-22	8.8.18	CVRDNSGYENYHYGMDVW
1000-1C03K	IGKV1-9	12	96	IGKJ2		6.3.9	CQQLNNYPYTF
1000-1D05H	IGHV3-30	15	95	IGHJ6	IGHD3-10	8.8.15	CAKAGLQRFSPHFMDVW
1000-1D05K	IGKV1-5	13	96	IGKJ4		6.3.10	CQQYHSHSKLTF
1000-1E04H (C7)	IGHV3-11	25	92	IGHJ4	IGHD5-24	8.8.12	CVRDLVWVQLPDYW
1000-1E04K (C7)	IGKV3-20	9	97	IGKJ1		7.3.9	CQQYGSSPTTF
1000-1F04H	IGHV3-7	19	93	IGHJ5	IGHD4-23	8.8.10	CARDFDRGAHEW
1000-1F04K	IGKV2-30	16	94	IGKJ1		11.3.9	CLQGTHWPRTF
1000-1H01H-A	IGHV3-11	18	94	IGHJ4	IGHD2-2	8.8.19	CARYYLAGNCRTSNCYVFDYW
1000-1H01K	IGKV1-9	8	97	IGKJ2		6.3.9	CQQLNSFPPTF
1000-2C02H	IGHV3-23	30	90	IGHJ3	IGHD3-9	8.8.21	CAKHVTGYLSCGEGGGGTLDVW
1000-2C02K	IGKV3-11	12	96	IGKJ4		6.3.9	CQQRINWPLTF
1000-2D04H-A	IGHV3-23	36	88	IGHJ4	IGHD6-19	8.8.7	CVKDDQWDYW
1000-2D04K	IGKV3-11	13	95	IGKJ4		6.3.9	CQQRNNWPLTF
1000-2F04H	IGHV4-4	15	95	IGHJ4	IGHD3-3	9.7.13	CVAVAFRAYALFDDW
1000-2F04K	IGKV3-20	7	98	IGKJ1		7.3.9	CQQYGSSPRTF
1000-2F06H-A	IGHV5-51	20	93	IGHJ4	IGHD3-9	8.8.17	CARHQVSAGYTGYYHFDYW
1000-2F06K	IGKV4-1	15	95	IGKJ3		12.3.9	CQQYSSPLTF
1000-2G06H	IGHV4-4	5	98	IGHJ6	IGHD4-4	9.7.14	CARERNRVYYYGMDVW
1000-2G06K	IGKV3-11	2	99	IGKJ4		6.3.6	CQQRNRTF
1000-3B04H (C4)	IGHV7-4-1	12	96	IGHJ4	IGHD2-15	8.8.14	CATRGPVVLGEALAYW
1000-3B04K (C4)	IGKV1-5	6	98	IGKJ1		6.3.8	CQQYNNYSGF
1000-3B06H (C4)	IGHV7-4-1	11	96	IGHJ4	IGHD2-2	8.8.14	CATRGPVVLGEALDSW
1000-3B06K (C4)	IGKV1-5	3	99	IGKJ1		6.3.8	CQQYNSYSGF
1000-3C02H	IGHV1-18	38	87	IGHJ4	IGHD2-15	8.8.16	CARDEGQYRGNDHFDYW
1000-3C02K	IGKV2-30	16	94	IGKJ1		11.3.9	CMQATHWPRTF
1000-3C05H	IGHV4-34	9	97	IGHJ6	IGHD5-24	8.7.18	CARGRGYATYYYYYVDVW
1000-3C05K	IGKV3-11	3	99	IGKJ4		6.3.8	CQQRSNWLTf
1000-3D04H	IGHV3-21	25	91	IGHJ4	IGHD3-22	8.8.12	CAREPYNDGYFESW
1000-3D04K	IGKV2-28	5	98	IGKJ2		11.3.9	CMQALQTPLTF
1000-3E01H	IGHV4-31	10	97	IGHJ3	IGHD4-17	10.7.14	CARDQNDYGEDPLDVW
1000-3E01K	IGKV4-1	9	97	IGKJ2		12.3.10	CQQYCGTPLYTF
1000-3E04H	IGHV4-61	14	95	IGHJ6	IGHD4-17	10.7.22	CARQVFYDNDHDLGYGLDVW
1000-3E04K	IGKV3-15	3	99	IGKJ1		6.3.8	CQQYNNWPTF
Donor-1009							
1009-3A02H	IGHV1-69	19	94	IGHJ6	IGHD1-1	8.8.19	CGRARRQVTLDNSFSYPMDVW
1009-3A02K	IGKV1-33	11	96	IGKJ4		6.3.9	CQHYDNVPPTF
1009-3B05H-A (C4)	IGHV1-69	23	92	IGHJ3	IGHD2-8	8.8.16	CATSAGGINVYLLFDIW
1009-3B05K (C4)	IGKV1-5	12	96	IGKJ1		6.3.9	CQHYNTYSSTF
1009-3B06H	IGHV4-39	23	92	IGHJ6	IGHD2-8	10.7.19	CARVNIYLVTVVEEYHYGMDVW
1009-3B06K	IGKV3-15	12	96	IGKJ3		6.3.11	CQHYNRWPLGFTF
1009-3C02H	IGHV3-9	18	95	IGHJ4	IGHD3-10	8.8.12	CARSNAGSYSES
1009-3C02K	IGKV3-15	11	96	IGKJ4		6.3.8	CQQYNNWPHF
1009-3C06H-A	IGHV4-b	5	98	IGHJ4	IGHD5-12	9.7.14	CARGRGATVTTTHFDYW
1009-3C06K	IGKV2-24	0	100	IGKJ5		11.3.10	CMQATQFPSTF
1009-3D01H	IGHV1-18	12	96	IGHJ4	IGHD2-2	8.8.16	CARMGIVVAPAVGSLDYW
1009-3D01K	IGKV3-20	7	98	IGKJ1		7.3.9	CQQYGTSPWTF
1009-3E04H (C3)	IGHV4-30-4	27	91	IGHJ3	IGHD4-17	10.7.14	CARDRDYGEDPFDIW
1009-3E04K	IGKV1-27	13	96	IGKJ4		6.3.9	CQKYNVSLPTF
1009-3E06H (C4)	IGHV1-69	31	89	IGHJ3	IGHD3-3	8.8.16	CATSAGGINVYLLSFNIW
1009-3E06K (C4)	IGKV1-5	25	91	IGKJ1		6.3.9	CQQYSTYSSTF
1009-3F01H	IGHV4-30-4	11	96	IGHJ6	IGHD3-3	10.7.23	CARDSRLLEWFTVDSYDYAMDVW
1009-3F01K	IGKV1-39	14	95	IGKJ1		6.3.9	CQQTYSPPRTF
1009-3G06H	IGHV1-69	16	94	IGHJ4	IGHD4-17	8.8.13	CARDSDYDIDYW
1009-3G06K	IGKV4-1	11	96	IGKJ1		12.3.9	CQQYSTSWTF
Donor-70							
70-1C04H	IGHV4-59	19	93	IGHJ3	IGHD3-10	8.7.15	CARDRTGAGDKNAFDVW
70-1C04K	IGKV1-39	18	94	IGKJ1		6.3.9	CQSYDTPQTF
70-1D02H	IGHV1-18	37	87	IGHJ3	IGHD1-1	8.8.21	CARGASSTGTMLRGKNAFDIW
70-1D02K	IGKV1-27	13	95	IGKJ2		6.3.9	CQVYISAPYTF
70-1F02H-A	IGHV1-69	12	96	IGHJ4	IGHD3-22	8.8.14	CARGPYYYGNSHLDWF
70-1F02K	IGKV3-20	7	98	IGKJ1		7.3.9	CQQYGTSPRTF
70-1F03H	IGHV1-69	39	86	IGHJ3	IGHD3-10	8.8.14	CARKDAGSAYKSFDVW
70-1F03K	IGKV2-28	17	94	IGKJ1		11.3.9	CMQSLQTPPTF
70-5B01H	IGHV1-69	23	92	IGHJ4	IGHD5-12	8.8.12	CARDGGWLRLTDSW

Supplemental table 1: Novel H1N1 Influenza-induced plasmablasts with detectable binding

NAME*	V-GENE	Mutations	V %ID	J-GENE	D-GENE	CDR-lengths	AA JUNCTION
70-5B01K	IGKV3-20	18	94	IGKJ3		7.3.11	CQYYVSSPRRFTF
70-5B03H	IGHV1-69	21	93	IGHJ4	IGHD1-26	8.8.14	CASSSGSYG DYFDYW
70-5B03K	IGKV3-15	7	97	IGKJ1		6.3.9	CQQYNNWPRTF
70-5C01H-A	IGHV3-23	6	95	IGHJ5	IGHD2-15	8.8.15	CARSTCGGSCYYRLDPW
70-5C01K	IGKV2-28	7	98	IGKJ3		11.3.9	CMQPLQTPFTF
70-5C05H	IGHV3-21	23	92	IGHJ4	IGHD6-19	8.8.13	CARSPGIAVGLIDYW
70-5C05K	IGKV3-20	11	96	IGKJ1		7.3.9	CQQYGRSPRTF
70-5D01H	IGHV5-51	20	93	IGHJ6	IGHD2-2	8.8.23	CARLGC GTTDCSPTW PYYYYGLDWW
70-5D01K	IGKV3-20	12	96	IGKJ5		7.3.8	CQQYGRSPFTF
70-5E05H	IGHV3-23	21	93	IGHJ4	IGHD2-15	8.8.18	CAKGLAYCSFGSCPYPLDYW
70-5E05K	IGKV4-1	18	94	IGKJ1		12.3.9	CQQYVTSPRTF
70-5F01H	IGHV1-69	19	93	IGHJ3	IGHD1-26	8.8.23	CARGRTSGSQDRLPLLWGLSGFDIW
70-5F01K	IGKV3-11	4	99	IGKJ4		6.3.8	CQQSSNWVTF
70-5G05H-A	IGHV3-9	16	95	IGHJ4	IGHD1-26	8.8.13	CTKAHSATHQGFDYW
70-5G05K	IGKV3-15	10	96	IGKJ2		6.3.10	CQQYNGWPLYTF
Donor-EM							
EM-2C04H	IGHV3-64	1	100	IGHJ6	IGHD3-3	8.8.20	CVNGGRAFGVVIKYYYYGMDVW
EM-2C04K	IGKV1-39	4	99	IGKJ5		6.3.9	CQQSYSTPITF
EM-2E01H (C3)	IGHV3-33	1	100	IGHJ4	IGHD6-19	8.8.13	CARDSESGGWYFDYW
EM-2E01K (C3)	IGKV3-15	0	100	IGKJ1		6.3.9	CQQYNNWPRTF
EM-3B01H	IGHV3-21	2	99	IGHJ6	IGHD3-3	8.8.18	CARRPSGFLEGGY YYYMDVW
EM-3B01K	IGKV3-15	0	100	IGKJ4		6.3.9	CQQYNNWPLTF
EM-3C02H (C3)	IGHV3-33	1	100	IGHJ4	IGHD6-19	8.8.13	CARDSESGGWYFDYW
EM-3C02K (C3)	IGKV1-39	3	99	IGKJ5		6.3.9	CQQSYSTPITF
EM-3C04H	IGHV4-28	20	93	IGHJ4	IGHD6-19	9.7.11	CALGLTSGWIDYW
EM-3C04K	IGKV1-5	8	97	IGKJ1		6.3.8	CQQYNSFRFTF
EM-4C04H	IGHV3-21	15	95	IGHJ4	IGHD5-12	8.8.18	CARAGLGTVDLRWGGA FDHW
EM-4C04K	IGKV1-33	15	95	IGKJ2		6.3.9	CQQYDDLPTYTF

*Clonal sequences are denoted by clonal pool number in parentheses: for example, clonal pool 1 from a particular patient is "(C1)."

Supplemental table 2: Novel H1N1 Influenza-induced plasmablasts with undetectable binding

NAME	V-GENE	Mutations	V %ID	J-GENE	D-GENE	CDR-lengths	AA JUNCTION
Donor-1000							
1000-1B01H-A (C1)	IGHV3-7	17	94	IGHJ5	IGHD4-23	8.8.10	CARDFDRGAHEHW
1000-1B01K (C1)	IGKV2-30	12	96	IGKJ1		11.3.9	CLQGTWHPRTF
1000-1E02H-A	IGHV3-72	22	93	IGHJ6	IGHD3-3	8.10.18	CTRDFLEWSRYYYYHFMDVW
1000-1E02K	IGKV4-1	12	96	IGKJ1		12.3.9	CQQYYTTPPTF
1000-1F05H	IGHV4-30-2	31	89	IGHJ3	IGHD3-16	10.7.10	CARAARGRLNIW
1000-1F05K	IGKV1-33	10	97	IGKJ3		6.3.11	CQQYDNLPIPTF
1000-1F06H-A	IGHV3-7	23	92	IGHJ4	IGHD1-7	8.8.11	CTRDSGITRFDYW
1000-1F06K	IGKV2-30	4	99	IGKJ5		11.3.9	CMQGTWHPAF
1000-1H04H	IGHV3-23	24	92	IGHJ3	IGHD3-22	8.8.22	CAKSLFSGTVDDNNGFYFDAFIW
1000-1H04K	IGKV3-11	9	97	IGKJ4		6.3.11	CQQRSNWPPTLTF
1000-2B03H-A (C1)	IGHV3-7	15	95	IGHJ4	IGHD6-6	8.8.10	CARTSSAYFDYW
1000-2B03K (C1)	IGKV3-11	7	97	IGKJ1		6.3.9	CQQRSNWPQTF
1000-2B05H-A	IGHV3-7	17	94	IGHJ4	IGHD4-4	8.8.10	CAKDAYSVDPYW
1000-2B05K	IGKV4-1	20	94	IGKJ1		12.3.9	CQHYYTEPTF
1000-2E06H-A	IGHV1-3	24	92	IGHJ4	IGHD2-2	8.8.15	CARPVRNGIAPSAIEYW
1000-2E06K	IGKV4-1	6	98	IGKJ3		12.3.8	CQQYYNTITF
1000-2H03H	IGHV5-a	20	93	IGHJ5	IGHD6-13	8.8.13	CARAAGGTLGWFDPW
1000-2H03K	IGKV1-5	0	100	IGKJ1		6.3.9	CQQYNSYPRTF
1000-3C04H	IGHV4-59	27	91	IGHJ3	IGHD6-19	8.7.19	CATSNLDYMGWHRGAFNIW
1000-3C04K	IGKV1-5	21	92	IGKJ3		6.3.9	CQQYNSYLFTF
1000-3D02H-A	IGHV1-69	20	93	IGHJ6	IGHD3-3	8.8.18	CARPGDYRTIRYYHFFMDVW
1000-3D02K	IGKV3-20	2	99	IGKJ1		7.3.10	CQQYGSSPPATF
1000-3F01H-A	IGHV3-7	18	94	IGHJ4	IGHD3-10	8.8.16	CATDREYEGKWSVDRFNW
1000-3F01K	IGKV1-16	10	96	IGKJ4		6.3.9	CQQYNSYPLTF
1000-3H05H-A	IGHV3-15	13	97	IGHJ4	IGHD1-1	8.10.8	CIADWHPEYW
1000-3H05K	IGKV2-30	7	98	IGKJ2		11.3.10	CMQTLWPPNTF
Donor-1009							
1009-3A05H	IGHV1-58	9	97	IGHJ6	IGHD6-6	8.8.15	CAAYFGGSASNYGLDWW
1009-3A05K	IGKV2-28	7	98	IGKJ4		11.3.9	CMQASQTPQTF
1009-3C04H	IGHV5-51	14	95	IGHJ3	IGHD6-13	8.8.15	CARPKYSSSSYSGFDDW
1009-3C04K	IGKV1-9	10	97	IGKJ4		6.3.9	CQQLHSSPLTF
1009-3G05H-A	IGHV3-7	16	95	IGHJ4	IGHD6-6	8.8.9	CAPETYYFDHW
1009-3G05K	IGKV3-11	15	94	IGKJ4		6.3.8	CQQRSQVLTF
Donor-70							
70-1B06H	IGHV3-9	20	93	IGHJ4	IGHD2-21	8.8.21	CAKDINTAQYCNIVNCYGEFDYW
70-1B06K	IGKV1-5	14	95	IGKJ4		6.3.8	CQQYDTPPTF
70-1C01H-A	IGHV1-2	31	89	IGHJ6	IGHD3-22	8.8.25	CARGGYQDSTGYHYDDDGPRYYGLDDW
70-1C01K	IGKV1-39	25	91	IGKJ5		6.3.9	CQQSYTPLITF
70-1D01H-A	IGHV3-48	46	84	IGHJ6	IGHD6-19	8.8.24	CARDPTPVAGRVRRAISDYQYAMDVW
70-1D01K	IGKV3-20	24	91	IGKJ2		7.3.10	CQHYGASPLYNF
70-1E04H-A	IGHV3-30	13	96	IGHJ4	IGHD3-22	8.8.15	CAKDADTTGYDDPFDDYW
70-1E04K	IGKV1-5	14	95	IGKJ2		6.3.8	CQQYHEYHSF
70-1G05H-A	IGHV4-39	31	89	IGHJ6	IGHD2-2	10.7.20	CATRGVEDCSGIDCSLYMEVW
70-1G05K	IGKV3-15	12	96	IGKJ4		6.3.9	CQYDNPVPTF
70-5A01H-A	IGHV3-48	29	90	IGHJ4	IGHD4-4	8.8.14	CARVAGRGYRDYTDVW
70-5A01K	IGKV1-16	16	94	IGKJ2		6.3.9	CQQYNSYPRTF
70-5D02H	IGHV4-39	46	84	IGHJ4	IGHD4-17	10.7.12	CARSSRSFGDYGDW
70-5D02K	IGKV3-11	15	94	IGKJ4		6.3.8	CQQRSQVLTF
70-5D04H-A	IGHV3-23	15	95	IGHJ4	IGHD3-10	8.8.14	CAKDSVFNFSGRDDHW
70-5D04K	IGKV3-11	8	97	IGKJ1		6.3.9	CHQRYNWPRTF
70-5E02H	IGHV3-11	25	91	IGHJ3	IGHD3-3	8.8.11	CARSTVIMPPDVW
70-5E02K	IGKV1-33	17	94	IGKJ3		6.3.9	CQQNHNVLNFN
Donor-EM							
EM-1A05H	IGHV4-59	0	100	IGHJ4	IGHD3-10	8.7.9	CARGGSGSYGW
EM-1A05K	IGKV1-16	0	100	IGKJ2		6.3.9	CQQYNSYPPTF
EM-2A02H	IGHV1-2	0	100	IGHJ4	IGHD3-22	8.8.17	CARANSDRYYYDSSGYSYW
EM-2A02K	IGKV1-39	0	100	IGKJ5		6.3.9	CQQSYSTPITF
EM-2C05H	IGHV3-9	3	99	IGHJ3	IGHD6-13	8.8.16	CAKAGIAAAGTNYAFDIW
EM-2C05K	IGKV3-15	1	100	IGKJ5		6.3.11	CQQYNNWPPVTF
EM-2F06H	IGHV1-69	1	100	IGHJ6	IGHD6-6	8.8.19	CARVVDIARPEGYYYMDVW
EM-2F06K	IGKV2-28	1	100	IGKJ1		11.3.8	CMQALQWTTF
EM-3A01H	IGHV3-30	2	99	IGHJ4	IGHD3-3	8.8.17	CARGLGLEWRLSPGYFDYW
EM-3A01K	IGKV3-15	1	100	IGKJ3		6.3.9	CQQYNNWPGTF
EM-3C03H	IGHV3-30	2	100	IGHJ4	IGHD5-12	8.8.13	CAKDSGEYEEYFDYW
EM-3C03K	IGKV1-39	3	99	IGKJ4		6.3.9	CQQSYSTPLTF
EM-3C05H (C5)	IGHV3-11	0	100	IGHJ4	IGHD6-19	8.8.15	CARDGDSSGWYARFDYW
EM-3C05K (C5)	IGKV3-15	1	100	IGKJ1		6.3.10	CQQYNNWPPWTF

Supplemental table 2: Novel H1N1 Influenza-induced plasmablasts with undetectable binding

NAME	V-GENE	Mutations	V %ID	J-GENE	D-GENE	CDR-lengths	AA JUNCTION
EM-3D04H	IGHV1-69	2	99	IGHJ6	IGHD3-10	8.8.17	CARARTVGFGESAYYMDVW
EM-3D04K	IGKV2-28	0	100	IGKJ2		11.3.8	CMQALHPCSF
EM-3E03H	IGHV3-15	0	100	IGHJ6	IGHD3-10	8.10.15	CTTDRWGSSYYYMDVW
EM-3E03K	IGKV2-28	0	100	IGKJ1		11.3.9	CMQALQTTWTF
EM-3F06H	IGHV3-7	3	99	IGHJ4	IGHD6-19	8.8.15	CARDADSSGWYAHFDYW
EM-3F06K	IGKV3-15	0	100	IGKJ1		6.3.10	CQQYNNWPPWTF
EM-4B01H	IGHV4-31	0	100	IGHJ5	IGHD3-3	10.7.16	CARNPDVYDFGSNWFDPW
EM-4B01K	IGKV1-33	0	100	IGKJ4		6.3.9	CQQYDNLPLTF
EM-4C01H (C1)	IGHV4-31	0	100	IGHJ4	IGHD3-3	10.7.18	CARAPDDFWSGYWGYFDYW
EM-4C01K (C1)	IGKV3-20	0	100	IGKJ1		7.3.8	CQQYGSSGTF
EM-8B06H	IGHV1-2	0	100	IGHJ6	IGHD6-6	8.8.16	CARGLHSSSDYYYGMDVW
EM-8B06K	IGKV1-27	0	100	IGKJ5		6.3.9	CQKYNSAPFTF
EM-8C04H	IGHV3-15	19	94	IGHJ4	IGHD1-14	8.10.10	CTTDPYPTFGYW
EM-8C04K	IGKV1-5	9	97	IGKJ1		6.3.9	CQQYNSYWWTF
EM-8G02H	IGHV3-30	3	99	IGHJ4	IGHD3-3	8.8.17	CAKDYTPYALEWLPLFDYW
EM-8G02K	IGKV3-15	4	99	IGKJ4		6.3.10	CQQYNKWPLPLTF

*Clonal sequences are denoted by clonal pool number in parentheses: for example, clonal pool 1 from a particular patient is "(C1)."

Supplemental Table 3: Sequence analysis only from novel H1N1-induced plasmablasts.

NAME	V-GENE	Mutations	V %ID	J-GENE	D-GENE	CDR-lengths	AA JUNCTION
Donor-1000							
1000-1B04H	IGHV1-69	12	96	IGHJ1	IGHD3-22	8.8.13	CARGMYYYESYLQHW
1000-1B06H	IGHV1-69	24	87	IGHJ6	IGHD2-2	8.8.12	CTVGDVVHYGLDWW
1000-1C04H (C2)	IGHV4-59	17	93	IGHJ6	IGHD3-16	8.7.18	CATRGTIGPFSYYYYMDVW
1000-1D02H-A	IGHV3-9	20	90	IGHJ4	IGHD2-8	2.8.14	CAKGDSPNMEYAFDSW
1000-1D04H	IGHV3-30	28	89	IGHJ4	IGHD5-5	8.8.16	CARQRGYNYGAKMYFDFW
1000-1F01H	IGHV3-33	12	95	IGHJ4	IGHD2-15	8.8.13	CARALRGGLTCLDFW
1000-1F02H (C3)	IGHV4-34	18	90	IGHJ5	IGHD3-3	8.7.20	CVRGLNQRASIFGDVRYWFDPW
1000-1G02H	IGHV3-73	20	92	IGHJ4	IGHD6-13	8.10.15	CTRANIITAGSSTFDYW
1000-1G05H	IGHV3-30-3	25	90	IGHJ4	IGHD3-3	8.8.16	CARDITIFGVARWTFDSW
1000-1H02H-A	IGHV3-30	34	87	IGHJ3	IGHD3-22	8.8.22	CGKDIKWTFDSSTYYDGDGDFDW
1000-1H03H (C2)	IGHV4-59	11	95	IGHJ6	IGHD3-16	8.7.18	CATRGTIGPFSYYYYMDVW
1000-2B02H-A	IGHV5-51	15	93	IGHJ3	IGHD3-10	8.8.18	CARGPWFGMSLYAARSFVW
1000-2B04H	IGHV3-7	17	94	IGHJ5	IGHD4-23	8.8.10	CARDFDRGAHEW
1000-2B06H-A	IGHV3-33	26	92	IGHJ2	IGHD2-15	8.8.19	CLREPREGGGGNAFYWYFDLW
1000-2D01H	IGHV1-8	22	92	IGHJ5	IGHD3-3	8.8.22	CARGLGNRITIGVLTNRNWLDPW
1000-2D05H	IGHV5-51	6	97	IGHJ4	IGHD2-8	8.8.18	CARSDDCTNGVCYTRHFDYW
1000-2E01H	IGHV4-30-2	31	87	IGHJ4	IGHD3-16	10.7.14	CARHETSPGGDYFNHW
1000-2F02H-A (C6)	IGHV3-7	33	89	IGHJ2	IGHD3-3	8.8.20	CASLKHNDGCFSGCPHWYLDLW
1000-2F03H	IGHV4-34	0	100	IGHJ6	IGHD2-2	8.7.29	CASSPIVVPAAPRELYSPGGYYYYMDVW
1000-2G03H-A	IGHV3-7	16	94	IGHJ3	IGHD3-10	8.8.11	CARDRGIDAFDIW
1000-2H01H-A (C6)	IGHV3-7	33	89	IGHJ2	IGHD2-2	8.8.20	CASLKHDDCYSTACPHWYFDLW
1000-2H06H-A	IGHV3-23	24	92	IGHJ6	IGHD2-2	8.8.18	CLTDQHDGCTASCHKMDVW
1000-3B02H-A	IGHV3-11	22	91	IGHJ4	IGHD4-23	8.8.16	CARYVGNRITYSYYFDYW
1000-3B05H	IGHV4-59	17	91	IGHJ4	IGHD3-22	8.7.15	CARVGMSDGYYYVDSW
1000-3C01H	IGHV3-7	26	89	IGHJ4	IGHD2-21	8.8.14	CARAGDWDYNPHFASW
1000-3C03H-A	IGHV1-46	25	89	IGHJ4	IGHD5-12	8.8.12	CARIRRGTSYDYW
1000-3D01H (C4)	IGHV7-4-1	14	94	IGHJ4	IGHD2-15	8.8.14	CATRGPPVVLGEALAYW
1000-3D03H-A	IGHV3-30	28	88	IGHJ4	IGHD2-8	8.8.16	CTNGLTGPAVNAEFEFW
1000-3E03H	IGHV3-23	14	95	IGHJ1	IGHD6-19	8.8.22	CVKVSGYASGWLAPFGPVGHLSHW
1000-3E06H-A	IGHV4-30-4	18	90	IGHJ4	IGHD7-27	8.7.15	CVGQKGKTNWGWGTMPYW
1000-3F02H-A	IGHV3-7	11	95	IGHJ3	IGHD4-23	8.8.9	CVGSGRSFDIW
1000-3F03H	IGHV4-61	25	91	IGHJ6	IGHD4-17	10.7.22	CARQVFDNDSDGLGYYYGLDWW
1000-3F04H (C3)	IGHV4-34	31	86	IGHJ5	IGHD3-3	8.7.20	CARGLNQRSSIFGVVRHCFDPW
1000-3F05H (C5)	IGHV1-69	38	84	IGHJ5	IGHD3-16	8.8.17	CARGEYAGVPTPNWFDPW
1000-3F06H-A	IGHV3-7	22	93	IGHJ4	IGHD3-10	8.8.11	CSRDDGGYFDYW
1000-3G03H-A (C5)	IGHV1-69	37	85	IGHJ5	IGHD3-16	8.8.17	CARGEYAGVPTPNWFDPW
1000-3G05H	IGHV3-33	8	97	IGHJ4	IGHD1-26	8.8.17	CAKDGPTSAHYVQWDFDYW
1000-3G06H	IGHV4-30-4	27	89	IGHJ5	IGHD3-16	10.7.11	CARGGVWFGSLRW
1000-3H06H	IGHV3-30	13	95	IGHJ6	IGHD2-15	8.8.22	CAKEYICSGGTCYSFRSYYYYMDVW
Donor-1009							
1009-3A01H-A	IGHV1-2	10	96	IGHJ4	IGHD5-24	8.8.10	CARLRDAYSDYW
1009-3A03H-A (C1)	IGHV3-9	20	92	IGHJ4	IGHD3-9	8.8.14	CAKDGRLRYFGFYLDWS
1009-3A04H	IGHV3-43	21	91	IGHJ6	IGHD1-26	8.8.15	CAKDSPPGYFFYGMVW
1009-3A06H-A	IGHV3-48	24	85	IGHJ4	IGHD3-3	8.8.15	CAXMGWLLVASYYFDHW
1009-3B01H-A	IGHV3-11	16	93	IGHJ4	IGHD2-8	8.8.21	CARVARICTNGACYEGAYFDNW
1009-3B03H	IGHV3-9	5	98	IGHJ6	IGHD5-5	8.8.23	CVKDKGYSSGYDDVAGYYWYTMVW
1009-3B04H-A	IGHV3-30	16	93	IGHJ6	IGHD1-14	8.8.17	CAKTRRITATRYYYGMDVW
1009-3D02H	IGHV5-51	21	90	IGHJ3	IGHD3-10	7.8.16	CVRRERPLRSGRAPFDTW
1009-3D03H	IGHV3-30	5	97	IGHJ4	IGHD3-3	8.8.17	CAKGSRYITIFGANPPDYW
1009-3D04H	IGHV4-39	15	92	IGHJ4	IGHD5-12	1.7.18	CARSRQRGYSSYDKGDFDYW
1009-3D05H-A	IGHV3-48	5	96	IGHJ2	IGHD3-3	8.4.19	CARDFHNTIFGVVIPRYFDLW
1009-3E01H (C2)	IGHV3-9	16	94	IGHJ4	IGHD3-10	8.8.15	CVKHSVGYAGSGSFDWS
1009-3E02H	IGHV3-9	20	92	IGHJ4	IGHD3-22	8.8.13	CAKDRSGYFYALHF
1009-3E03H	IGHV3-74	17	93	IGHJ4	IGHD6-13	8.8.14	CARCPVATPGRGVYDW
1009-3F02H (C2)	IGHV3-9	23	91	IGHJ4	IGHD3-10	8.8.15	CVKHNGLGYSGGTFDYW
1009-3F03H-A	IGHV1-69	24	72	IGHJ4	IGHD6-6	3.8.19	AVYKARGATYRSSGYWEYW
1009-3F05H	IGHV3-30	14	95	IGHJ4	IGHD3-10	8.8.14	CAKDPYSGSGSYSQYW
1009-3F06H (C3)	IGHV4-31	23	90	IGHJ3	IGHD4-17	10.7.14	CARDRHDYGEDPFDIW
1009-3G02H-A (C1)	IGHV3-9	23	90	IGHJ4	IGHD3-9	8.8.14	CAKDGRLRYFGFYLDWS
1009-3G04H	IGHV3-23	33	87	IGHJ4	IGHD1-14	8.8.15	CTREAGLWPEPYFDWS
Donor-1010							
1010-3A01H-A	IGHV4-61	10	96	IGHJ4	IGHD3-22	10.7.15	CARQPGRDSSGYLDWS
1010-3A02H-A	IGHV3-30	10	96	IGHJ5	IGHD2-2	8.8.20	CAKRSADCSSTSCSGGSWFDPW
1010-3A03H	IGHV3-11	24	90	IGHJ4	IGHD2-21	8.8.13	CARTIGIVTTYFEYW
1010-3A04H	IGHV1-46	27	59	IGHJ4	IGHD3-10	8.8.16	CARDRGDVLVAQGAIGYW
1010-3A05H-A	IGHV4-61	36	86	IGHJ5	IGHD6-13	10.7.14	CARLHYSTTWHYFDPW
1010-3B01H-A	IGHV3-48	23	91	IGHJ5	IGHD1-26	8.8.16	CARDSEATTTRGRWFDPW

Supplemental Table 3: Sequence analysis only from novel H1N1-induced plasmablasts.

NAME	V-GENE	Mutations	V %ID	J-GENE	D-GENE	CDR-lengths	AA JUNCTION
1010-3B03H-A	IGHV3-30	10	96	IGHJ6	IGHD1-26	8.8.18	CAKAGDSGSSSHCYYYMDVW
1010-3B04H	IGHV3-23	19	92	IGHJ5	IGHD3-16	8.7.20	CAKNRNYRPSGDFAEHGWLDPW
1010-3B05H-A	IGHV3-23	23	91	IGHJ6	IGHD6-19	8.8.15	CTKVDSSPFFDYGMVDVW
1010-3B06H-A	IGHV3-7	20	92	IGHJ4	IGHD4-4	8.8.17	CARDLLKPPNIDPTVKGLW
1010-3C01H	IGHV3-49	3	99	IGHJ4	IGHD5-5	8.10.20	CTRDIRGGYSYGFVPPYFDYW
1010-3C02H	IGHV4-b	11	95	IGHJ4	IGHD3-10	9.7.17	CARMGFVGSFTSGTYIDYW
1010-3D01H	IGHV1-18	16	93	IGHJ4	IGHD3-3	8.8.14	CARIHDFRSGFFLDYW
1010-3D02H-A	IGHV1-2	27	88	IGHJ3	IGHD2-2	8.8.21	CARDDCSITTCRVPNQDHAFDIW
1010-3E01H-A	IGHV4-59	7	97	IGHJ4	IGHD3-22	8.7.16	CARAAWRDGNMGYFLDYW
1010-3E06H	IGHV4-4	30	88	IGHJ4	IGHD3-9	9.7.12	CAKRGDWLWYFDVW
1010-3F01H-A	IGHV4-39	36	85	IGHJ6	IGHD3-10	10.7.22	CARLVPAEPSGPGNYFYFFMDVW
1010-3F02H	IGHV3-48	0	100	IGHJ6	IGHD4-17	8.1.11	CARGTTATGMDVW
1010-3G01H-A	IGHV3-53	27	88	IGHJ4	IGHD6-13	8.7.12	CARVGRRSWYVDYW
1010-3G03H-A	IGHV3-7	27	89	IGHJ4	IGHD5-24	8.8.7	CTRGDPDYW
1010-3G04H	IGHV4-b	12	95	IGHJ4	IGHD6-6	9.7.17	CARKVRGSSPDPLYFDYW
1010-3G06H	IGHV3-15	34	86	IGHJ5	IGHD3-10	8.10.13	CTRNSPITVFGVGPW
Donor-1011							
1011-3A01H (C1)	IGHV1-69	21	91	IGHJ6	IGHD3-10	8.8.14	CARGLNYYYYHGMVDVW
1011-3A02H (C1)	IGHV1-69	37	85	IGHJ6	IGHD5-24	8.8.14	CARGLNYYYYHGMVDVW
1011-3B03H-A	IGHV3-23	14	94	IGHJ4	IGHD3-16	8.8.16	CAKLRRGVMLIKYFDFW
1011-3B04H	IGHV3-48	33	87	IGHJ6	IGHD3-3	8.8.14	CARDAGRFLAYGMVDVW
1011-3B05H	IGHV3-11	32	85	IGHJ4	IGHD1-26	6.8.12	CATGYGFVGPLAYW
1011-3B06H	IGHV3-15	22	90	IGHJ4	IGHD3-16	8.10.9	CYGGDTEVRYW
1011-3C01H	IGHV1-69	34	86	IGHJ4	IGHD5-5	8.8.16	CVRCFGYNSNTPAYFDYW
1011-3C02H	IGHV3-21	17	93	IGHJ4	IGHD3-9	8.8.16	CARDFRPYDLLTGLFDSW
1011-3C03H-A	IGHV1-46	15	94	IGHJ4	IGHD5-24	8.8.12	CATFSQGGQLQNDYW
1011-3C05H	IGHV3-7	15	94	IGHJ6	IGHD2-2	8.8.11	CAIVSRSFVMDVW
1011-3D01H	IGHV3-48	18	92	IGHJ4	IGHD5-5	8.8.16	CAKTLRKRNYSGPIDSW
1011-3D02H	IGHV4-59	23	90	IGHJ3	IGHD3-22	8.7.15	CARDDTGISKNAFDIW
1011-3D03H	IGHV1-18	14	94	IGHJ3	IGHD4-17	8.8.19	CARDNLPSLYGDYDRNAFDIW
1011-3D05H	IGHV1-69	15	94	IGHJ4	IGHD1-26	8.8.13	CAKGRNYYVDYFDYW
1011-3E05H (C1)	IGHV1-69	37	85	IGHJ6	IGHD3-22	8.8.14	CARGLNYYYYHGMVDVW
1011-3E06H-A	IGHV3-7	22	89	IGHJ4	IGHD5-12	2.8.15	CARDSRIVPTNYYYDFW
1011-3F01H	IGHV3-11	18	92	IGHJ4	IGHD2-21	8.8.12	CARDPGGSSSFYDW
1011-3F02H	IGHV3-21	10	93	IGHJ2	IGHD2-21	8.8.18	CARVRCGGLCYSSDWYFDVW
1011-3F03H (C1)	IGHV1-69	24	90	IGHJ6	IGHD3-3	8.8.14	CARGLNYYYYHGMDLW
1011-3G01H (C1)	IGHV1-69	35	86	IGHJ6	IGHD3-9	8.8.14	CAKGLNYYYYHGMVDVW
1011-3G02H	IGHV3-23	22	91	IGHJ6	IGHD4-17	8.8.20	CAKDTATVTTSLYFYHGMVDVW
Donor-70							
70-1A03H-A	IGHV3-23	24	90	IGHJ4	IGHD4-4	8.8.16	CAKSQGPFFSYDYVFESW
70-1B03H (C1)	IGHV3-7	13	95	IGHJ6	IGHD3-16	8.8.18	CAREGSYGDYHSSYGMVDVW
70-1C02H	IGHV3-15	23	93	IGHJ4	IGHD6-6	8.10.14	CTADLTSSGHYFDYW
70-1C03H-A	IGHV3-7	11	95	IGHJ4	IGHD3-16	8.8.12	CARHSYALPPRDYW
70-1C06H-A	IGHV4-59	28	87	IGHJ4	IGHD2-21	8.7.13	CARGGGWLQSDFDIW
70-1D05H	IGHV1-69	27	89	IGHJ6	IGHD6-19	8.8.20	CASSGWPSDRYFHHYSGLDVW
70-1D06H	IGHV5-51	46	82	IGHJ4	IGHD4-4	8.8.9	CAGHTSTTNFW
70-1E02H	IGHV1-2	11	95	IGHJ5	IGHD2-2	8.8.13	CARGDCTSTSCYVHW
70-1E06H-A (C2)	IGHV6-1	32	81	IGHJ2	IGHD4-17	8.9.20	CVREGREYGRFSVPNWFYDLW
70-1F01H-A	IGHV4-61	37	85	IGHJ3	IGHD6-19	10.7.18	CARHPSYLAVADGRDAFDIW
70-1F04H-A	IGHV4-39	15	95	IGHJ5	IGHD3-3	10.7.19	CARQPPITIFGLLRPGWFGSW
70-1F05H (C1)	IGHV3-7	10	96	IGHJ6	IGHD3-16	8.8.18	CAREGSYGDYHSSYAMDVW
70-1G03H-A (C2)	IGHV6-1	13	94	IGHJ2	IGHD4-17	7.9.20	CAREGREYGRFSVPYWFYDLW
70-1G04H-A	IGHV3-23	19	93	IGHJ4	IGHD2-21	8.8.13	CARGVFSPAYYFEYW
70-1G06H-A	IGHV3-23	31	89	IGHJ2	IGHD6-19	8.8.13	CAKIAVSGQWYFDLW
70-5A06H	IGHV1-69	29	90	IGHJ4	IGHD3-22	8.8.11	CVVFITPTINYTW
70-5B06H-A	IGHV4-39	15	94	IGHJ6	IGHD6-19	10.7.19	CARLGGTGLNGGDFQYGVDIW
70-5C02H-A	IGHV1-69	19	92	IGHJ6	IGHD2-2	8.8.22	CSRLNPSRRPPGVPHYYGMDVW
70-5C06H	IGHV3-23	16	87	IGHJ5	IGHD1-14	8.1.16	CTSCWPILNHYSRPSW
70-5D03H-A	IGHV1-69	23	90	IGHJ6	IGHD3-10	8.8.14	CASALRYSFVYGMVDVW
70-5D06H	IGHV3-30	13	96	IGHJ4	IGHD6-19	8.8.13	CVKDAYNSGWHFYDW
70-5E01H-A	IGHV3-15	19	92	IGHJ4	IGHD7-27	8.10.9	CTKQTGDFDSW
70-5E03H-A	IGHV3-11	38	83	IGHJ4	IGHD2-21	8.8.16	CVSSYCRGNCCYGAPNYW
70-5E04H-A (C1)	IGHV3-7	9	96	IGHJ6	IGHD3-16	8.8.18	CAREGSYGDYHFFYAMDVW
70-5F02H	IGHV3-9	12	96	IGHJ2	IGHD4-4	8.8.8	CVTQQSFDLW
70-5F03H	IGHV1-2	34	88	IGHJ3	IGHD3-9	8.8.12	CAKILPGIYAFDLW
70-5F05H-A	IGHV4-39	26	87	IGHJ4	IGHD5-5	2.7.16	CARTGYSFDYSDYFDFW
70-5G02H-A	IGHV3-15	31	90	IGHJ6	IGHD2-8	8.10.14	CAIPPVPPYYYYSDVW
70-5G06H	IGHV4-39	34	88	IGHJ4	IGHD3-3	10.7.19	CARQRRVSIFGLLLPGEFDTW

Supplemental Table 3: Sequence analysis only from novel H1N1-induced plasmablasts.

NAME	V-GENE	Mutations	V %ID	J-GENE	D-GENE	CDR-lengths	AA JUNCTION
Donor-EM							
EM-1A02H	IGHV4-39	2	99	IGHJ2	IGHD2-2	10.7.21	CARHNDHYCSSTSCYPVGYFDLW
EM-1A03H	IGHV1-2	26	90	IGHJ4	IGHD3-22	8.8.20	CARALYYDSGSPVLYYFDYW
EM-1A04H	IGHV4-39	1	100	IGHJ4	IGHD3-16	10.7.14	CARLPRGDTLYYFDYW
EM-1B01H	IGHV3-23	25	90	IGHJ4	IGHD7-27	8.8.13	CAKGANWGSWFLDSW
EM-1B02H	IGHV4-39	0	100	IGHJ6	IGHD3-3	10.7.21	CAGRRGYDFWSGYNNYYGMDVW
EM-1B03H	IGHV3-30	1	100	IGHJ4	IGHD2-21	8.8.18	CAKEGWAYCGGDCYSYFDYW
EM-1B04H (C4)	IGHV4-59	11	96	IGHJ5	IGHD4-23	8.7.17	CARGKRGGNPDFSQRFPDW
EM-1B06H	IGHV3-49	11	96	IGHJ6	IGHD5-5	8.10.22	CARGGHTAMVTTPYFYNNYYGMDVW
EM-1C01H (C1)	IGHV4-31	3	99	IGHJ4	IGHD3-3	10.7.18	CARAPDDFWSGYWGYFFDYW
EM-1C03H	IGHV3-43	1	100	IGHJ2	IGHD1-26	8.8.18	CANSEWELLGPSTWWYFDLW
EM-1C04H	IGHV1-2	2	99	IGHJ1	IGHD1-26	8.8.10	CAREEGGSYFDW
EM-1C06H (C6)	IGHV4-39	2	100	IGHJ4	IGHD1-7	10.7.18	CGRHAVTTWYNWNYHPFDYW
EM-1D04H	IGHV4-39	2	99	IGHJ5	IGHD4-17	10.7.16	CARHPVNYGDYVEWFPDW
EM-1D05H (C3)	IGHV3-33	1	100	IGHJ4	IGHD6-19	8.8.13	CARDSESGWYFDYW
EM-1E01H	IGHV3-30	25	90	IGHJ6	IGHD1-26	8.8.20	CAKVGWSLQWLNLYGSDMDVW
EM-1E03H	IGHV1-18	0	100	IGHJ5	IGHD3-10	8.8.20	CARSHTSGSYLWRDLPLYWFPDW
EM-1F04H	IGHV3-11	1	100	IGHJ6	IGHD6-13	8.8.25	CAREGHRHSSRWRTGYNNYYMDVW
EM-1F05H	IGHV4-31	13	95	IGHJ2	IGHD6-6	10.7.18	CARDSNEAARGSEYWFYFDLW
EM-1F06H	IGHV5-a	8	97	IGHJ6	IGHD3-22	8.8.20	CARQDYDSSGYSYFYGMDVW
EM-2A06H	IGHV3-30	1	100	IGHJ4	IGHD2-8	8.8.19	CAKDQSGFVLMVYAIHSPGYW
EM-2B01H	IGHV3-43	0	100	IGHJ4	IGHD4-17	8.8.6	CAKDGGDL
EM-2B04H	IGHV3-7	1	100	IGHJ5	IGHD6-13	8.8.16	CAREGSSSWEFYNWFPDW
EM-2B05H	IGHV3-53	10	96	IGHJ6	IGHD3-10	8.7.13	CAKLMVDLDYMDVW
EM-2B06H	IGHV1-2	2	99	IGHJ5	IGHD4-4	8.8.17	CARDPTPYNAQLCWFPDW
EM-2D03H	IGHV3-43	0	100	IGHJ6	IGHD5-5	8.8.15	CAKDPLRYSSLYGMDVW
EM-2D04H	IGHV4-31	2	99	IGHJ6	IGHD3-9	10.7.18	CARGQDYDILTRSSYYMDVW
EM-2E03H	IGHV4-59	12	95	IGHJ4	IGHD4-4	8.7.15	CARESHDYSNYRFFDSW
EM-2E04H	IGHV1-2	0	100	IGHJ6	IGHD2-2	8.8.24	CASPLGYCSSTSCYRTYNNYYGMDVW
EM-2E05H	IGHV4-39	3	99	IGHJ5	IGHD2-21	10.7.17	CARLTVPSIRSWSSRFDPW
EM-2F02H	IGHV3-13	0	100	IGHJ6	IGHD6-6	8.7.8	CARDLSMDVW
EM-3A04H	IGHV3-9	3	99	IGHJ4	IGHD1-26	8.8.11	CSQGDGTGFGHYW
EM-3B02H	IGHV3-30	1	100	IGHJ4	IGHD4-17	8.8.12	CARIHYGDYFVDSW
EM-3C01H	IGHV3-15	12	96	IGHJ4	IGHD2-8	8.10.9	CTTGTTYFDYW
EM-3C06H (C6)	IGHV4-39	2	99	IGHJ4	IGHD1-7	10.7.18	CARHAVTTWYNWNYHPFDYW
EM-3D01H	IGHV3-64	4	99	IGHJ1	IGHD2-21	8.8.14	CARDGGDEFAEYFQHW
EM-3D02H	IGHV4-39	1	100	IGHJ6	IGHD1-7	10.7.19	CASQVGLRVVISYNNYYMDVW
EM-3D06H	IGHV4-39	4	98	IGHJ3	IGHD6-6	10.7.16	CARHPVEYSSLAGAFDIW
EM-3E01H	IGHV5-51	9	97	IGHJ6	IGHD7-27	8.8.17	CARQGAGDLPYKYFFMDVW
EM-3E02H	IGHV4-39	3	99	IGHJ4	IGHD6-6	10.7.15	CARHPVEYSSSSGFDYW
EM-3E04H	IGHV4-39	1	100	IGHJ4	IGHD3-3	10.7.16	CASLYYDFWSGYFGGDYW
EM-3F03H	IGHV4-31	1	100	IGHJ4	IGHD1-7	10.7.17	CARSTPYNNWNSPAPFDYW
EM-3F04H	IGHV3-33	3	99	IGHJ2	IGHD5-24	8.8.11	CARDRENWYFDLW
EM-3G04H (C5)	IGHV3-11	1	100	IGHJ4	IGHD6-19	8.8.15	CARDGSSSGWYARFDYW
EM-3G05H	IGHV4-30-4	30	83	IGHJ6	IGHD3-10	10.7.14	CARGLRDLPLSWYLDVW
EM-4A03H (C2)	IGHV3-11	1	100	IGHJ4	IGHD3-9	8.8.17	CARDPDQLFVQDPYFFDYW
EM-4B06H (C7)	IGHV3-21	0	100	IGHJ6	IGHD3-3	8.8.21	CARGSLDDFWSGWIEDYYMDVW
EM-4C02H (C7)	IGHV3-21	0	100	IGHJ6	IGHD3-3	8.8.21	CARGSLDDFWSGWIEDYYMDVW
EM-4C06H (C2)	IGHV3-11	1	100	IGHJ4	IGHD3-9	8.8.17	CARDPDQLFVQDPYFFDYW
EM-4D02H	IGHV3-43	0	100	IGHJ5	IGHD1-26	8.8.17	CAKDPTPYSGRYFTWFPDW
EM-4D03H	IGHV3-11	12	96	IGHJ4	IGHD3-3	8.8.17	CARDPGGFGVAPYFFDYW
EM-4D04H	IGHV4-39	1	100	IGHJ5	IGHD4-17	10.7.16	CARHPVNYGDYVEWFPDW
EM-4D06H (C3)	IGHV3-33	1	100	IGHJ4	IGHD6-19	8.8.13	CARDSESGWYFDYW
EM-4E01H	IGHV3-48	3	99	IGHJ3	IGHD3-3	8.8.22	CARVGTERITIFGVVISAAMDVW
EM-4E04H	IGHV3-21	3	99	IGHJ6	IGHD1-1	8.8.19	CARSVYDTPMTYNNYYMDVW
EM-4E05H	IGHV1-46	0	100	IGHJ4	IGHD3-10	8.8.16	CARGVLLWFGENENNDYW
EM-8A02H	IGHV3-48	0	100	IGHJ4	IGHD2-15	8.1.18	CARRGACGSGGSLPFDYW
EM-8A05H	IGHV4-39	2	99	IGHJ4	IGHD6-6	10.7.15	CARHGVEYSTSSCFDYW
EM-8A06H	IGHV4-30-4	2	99	IGHJ4	IGHD6-6	10.7.13	CARGRSGSSWDFGYW
EM-8B01H (C4)	IGHV4-59	14	94	IGHJ5	IGHD4-23	8.7.17	CARGKRGGNPDFSQRFPDW
EM-8B02H (C2)	IGHV3-11	1	100	IGHJ4	IGHD3-9	8.8.17	CARDPDQLFVQDPYFFDYW
EM-8B04H	IGHV5-a	31	88	IGHJ4	IGHD6-13	8.8.9	CARQRSEHDYW
EM-8B05H	IGHV4-59	20	92	IGHJ3	IGHD5-24	8.7.14	CARPSREGYLDYFDVW
EM-8C01H	IGHV1-2	0	100	IGHJ6	IGHD5-12	8.8.22	CATSTLNIVATIGPHYNNYYGMDVW
EM-8D02H (C2)	IGHV3-11	1	100	IGHJ4	IGHD3-9	8.8.17	CARDPDQLFVQDPYFFDYW
EM-8D06H	IGHV4-39	1	100	IGHJ4	IGHD3-16	10.7.14	CARHLRGDFVGQFDYW
EM-8E01H (C7)	IGHV3-21	0	100	IGHJ6	IGHD3-3	8.8.21	CARGSLDDFWSGWIEDYYMDVW
EM-8E02H	IGHV4-39	1	100	IGHJ4	IGHD3-3	10.7.18	CAGKTYDFWSGYPIKVVDYW

Supplemental Table 3: Sequence analysis only from novel H1N1-induced plasmablasts.

NAME	V-GENE	Mutations	V %ID	J-GENE	D-GENE	CDR-lengths	AA JUNCTION
EM-8E03H (C1)	IGHV4-31	5	98	IGHJ4	IGHD3-3	10.7.18	CARAPDDFWSGYWGYFFDYW
EM-8E05H	IGHV4-39	2	99	IGHJ6	IGHD1-26	10.7.19	CARLKGGWELLIYYYYMDVW
EM-8F01H	IGHV4-39	1	100	IGHJ4	IGHD6-6	10.7.15	CARRGEGYSSSSSFYDW
EM-8F04H	IGHV3-30	2	100	IGHJ4	IGHD5-12	8.8.13	CAKDSEGYEYFFDYW
EM-8F05H	IGHV3-33	19	92	IGHJ5	IGHD1-26	8.8.13	CGRVAGGTYSWFDFW
EM-8G01H	IGHV3-21	0	100	IGHJ4	IGHD5-5	8.8.17	CASLRVDTAMVTWGDQDYW
EM-8G04H (C2)	IGHV3-11	1	100	IGHJ4	IGHD3-9	8.8.17	CARDPDQLFVQDPYFFDYW
EM-8G06H	IGHV1-2	3	99	IGHJ4	IGHD3-3	8.8.26	CARIGVKGGSYDFWSGYYPNPGGYFDYW

*Clonal sequences are denoted by clonal pool number in parentheses: for example, clonal pool 1 from a particular patient is "(C1)."

SUPPLEMENTAL MATERIAL



Wrarmert et al., <http://www.jem.org/cgi/content/full/jem.20101352/DC1>

Figure S1. Binding characteristics of control mAbs. (A) Naïve antibody cross-reactivity levels were used to establish thresholds for scoring antibodies as positive against the pandemic H1N1 influenza strains. A set of 48 naïve antibodies were screened by ELISA for binding to the pandemic H1N1 influenza strain at concentrations beginning at 10 $\mu\text{g/ml}$ and three threefold dilutions (the same initial concentration used to test the anti-H1N1 plasmablast antibodies). We assigned the minimum binding threshold at two standard deviations (2xSD) above the mean absorbance for the naïve antibodies at 10 $\mu\text{g/ml}$ (left). Overall binding of curves of the naïve antibodies relative to this threshold are also provided. All ELISA assays were performed in duplicate. (B) Annual vaccine induced antibodies generated against past influenza strains before the 2009 pandemic H1N1 pandemic are only approximately one-third (22%) as likely to cross-react with the pandemic H1N1 strain than the inverse (Fig. 2, A and B; 63% of the pandemic H1N1-induced antibodies cross-react with past annual strains). We had generated 50 mAbs following annual vaccination before the pandemic. Binding of these prepandemic mAbs to annual strains is presented in the left panel and to the pandemic H1N1 strain on the right panel. These analyses were performed at least twice.



*1009-3B06 binds HA only on the whole virions and so curves are to virus when available (rows 1,2,5,6,7)

B Avidity estimates for the novel-H1N1 neutralizing mAbs

ANTIBODY	ka (1/Ms)	kd(1/s)	KD(M)
EM-4C04	2.68e5	2.78e-4	1.04e-9
1009-3F01	3.66e5	9.12e-4	2.49e-9
1009-3E06	2.43e5	6.78e-4	2.78e-9
1009-3E04	6.18e3	1.36e-3	2.2e-7
1009-3B05	2.76e5	2.04e-3	7.38e-9
1009-3B06			(4.14e-9)
70-1F02	3.08e5	1.23e-3	4.24e-9
70-5B03	5.37e5	1.26e-3	2.35e-9
1000-3D04	2.21e4	3.33e-4	1.87e-8
1000-3E01			(1.8e-7)
1000-2G06			(2.8e-8)

Figure S2. Binding characteristics of the neutralizing mAbs. (A) ELISA binding curves for multiple recombinant HA proteins and whole purified virus from different influenza strains for the 11 mAbs that neutralize pandemic H1N1 infectivity in vitro. These data were used for the summary analysis in Fig. 3 (A and C). The ELISA assays were performed at least twice. (B) Antibody avidities were determined by Biacore surface plasmon resonance (SPR) and ELISA. Antibodies 1009-3B06, 1000-3E01, and 1000-2G06 could not be determined because these mAbs did not bind to the recombinant HA protein from baculovirus sufficiently well for SPR. Avidities for these mAbs and for the antibodies that did not neutralize infection in vitro were estimated by Scatchard plot analyses of ELISA data (shown in parentheses). Three replicates were performed for the SPR analyses.




Figure S3. Pandemic H1N1-induced plasmablasts have accumulated large numbers of somatic mutations. (A) Similar to the results based on mutations averaged by donor, mutation frequency considered by each individual VH gene are also particularly high in the pandemic H1N1 patient plasmablast samples, comparable to annual influenza and repeated anthrax-booster responses. (B) Analysis of the variable gene repertoire indicated that cross-reactive antibodies binding pandemic H1N1 better than annual H1N1 strains have significantly more combined VH and VL mutations, suggesting accumulation after further affinity maturation of memory cells. Extraction of mutation numbers from the broadly cross-reactive antibodies indicates that, in general, they are from highly mutated variable genes as well. Statistical comparisons were made using Student's *t* tests. The data points (variable genes) are grouped by hypothetical origins as described in the text. In total, the variable genes encoding cross-reactive antibodies as a single grouping also had significantly more somatic mutations than the pandemic H1N1-specific antibody genes ($P = 0.03$). The frequency of mutations was significantly greater than the IgG controls for all donors except EM (Student's *t* test $P < 0.05$).




Figure S4. Therapeutic control of pandemic H1N1 viral titers in lungs after mAb treatment. 6–8-wk-old BALB/c mice were infected with a lethal 3xLD50 dose of mouse adapted pandemic H1N1 and treated with 200 μ g given i.p. EM4C04 48 h later. Lung tissue was removed from groups of 5 mice per time point at 4, 6, and 12 d after infection. Lung viral titers were determined by plaque assay on MDCK cells and are reported as pfu per gram tissue.